U.S. patent application number 12/191561 was filed with the patent office on 2008-12-18 for substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses.
Invention is credited to Zhidong Chen, Pier Francesco Cirillo, Darren DiSalvo, Weimin Liu, Daniel Richard Marshall, Lifen Wu, Erick Richard Roush Young.
Application Number | 20080312185 12/191561 |
Document ID | / |
Family ID | 34676758 |
Filed Date | 2008-12-18 |
United States Patent
Application |
20080312185 |
Kind Code |
A1 |
Chen; Zhidong ; et
al. |
December 18, 2008 |
SUBSTITUTED 3-AMINO-THIENO[2,3-b]PYRIDINE-2-CARBOXYLIC ACID AMIDE
COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES
Abstract
Disclosed are methods of treating cancer by administration of
compounds according to formula (I): ##STR00001## wherein the
variables R.sub.1, R.sub.2, R.sub.3 and Z are described herein.
Inventors: |
Chen; Zhidong; (New Milford,
CT) ; Cirillo; Pier Francesco; (woodbury, CT)
; DiSalvo; Darren; (New Milford, CT) ; Liu;
Weimin; (Sandy Hook, CT) ; Marshall; Daniel
Richard; (Sandy Hook, CT) ; Wu; Lifen; (New
Milford, CT) ; Young; Erick Richard Roush; (Danbury,
CT) |
Correspondence
Address: |
MICHAEL P. MORRIS;BOEHRINGER INGELHEIM USA CORPORATION
900 RIDGEBURY RD, P. O. BOX 368
RIDGEFIELD
CT
06877-0368
US
|
Family ID: |
34676758 |
Appl. No.: |
12/191561 |
Filed: |
August 14, 2008 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11500237 |
Aug 7, 2006 |
|
|
|
12191561 |
|
|
|
|
11002828 |
Dec 2, 2004 |
7119102 |
|
|
11500237 |
|
|
|
|
60527522 |
Dec 5, 2003 |
|
|
|
Current U.S.
Class: |
514/63 ; 514/274;
514/301 |
Current CPC
Class: |
A61P 27/02 20180101;
A61P 37/02 20180101; A61P 21/04 20180101; A61P 1/00 20180101; A61P
9/10 20180101; A61P 17/00 20180101; A61P 9/08 20180101; A61P 29/00
20180101; A61P 35/02 20180101; A61P 11/06 20180101; A61P 19/02
20180101; A61P 31/04 20180101; A61P 1/18 20180101; A61P 37/06
20180101; A61P 17/06 20180101; C07D 495/04 20130101; A61P 1/04
20180101; A61P 35/00 20180101; A61P 3/10 20180101; A61P 13/12
20180101; A61P 25/00 20180101; A61P 25/04 20180101; A61P 7/00
20180101; A61P 25/28 20180101; A61P 11/00 20180101; A61P 15/00
20180101; A61P 17/02 20180101 |
Class at
Publication: |
514/63 ; 514/301;
514/274 |
International
Class: |
A61K 31/695 20060101
A61K031/695; A61K 31/4365 20060101 A61K031/4365; A61K 31/506
20060101 A61K031/506; A61P 35/00 20060101 A61P035/00 |
Claims
1. A method of treating a cancer disease selected from lymphoid-,
myeloid- and epithelial-derived malignancies, leukemia, lymphomas,
breast cancer, gastric cancer, colorectal cancer, lung cancer, and
pancreatic cancer, said method comprising administering to a
patient in need of such treatment a therapeutically effective
amount of a compound according to general formula I: ##STR00148##
wherein: R.sub.1 is (a) phenyl or heteroaryl selected from furanyl,
thienyl, pyridyl, pyrrolyl, imidazolyl and benzofuranyl, optionally
substituted with one to two R.sub.4, (b) heterocyclyl selected from
1-piperidinyl, 1-piperazinyl, 1-pyrrolidinyl and 4-morpholinyl,
optionally substituted with one to two groups selected from
C.sub.1-6alkyl, --CO.sub.2C.sub.1-5alkyl, phenyl, benzyl, --OH and
--C(O)heteroaryl, wherein the heteroaryl is selected from furanyl,
thienyl, pyridyl and pyrrolyl, (c) R.sub.7(CH.sub.2).sub.mO--, (d)
R.sub.7OCH.sub.2--, (e) R.sub.7(CH.sub.2).sub.mNH--, (f)
R.sub.7(CH.sub.2).sub.p(CH.dbd.CH).sub.m--, (g) C.sub.1-6alkyl,
optionally partially or fully halogenated and optionally
substituted with one to two R.sub.8, (h) C.sub.1-8alkoxy,
optionally partially or fully halogenated and optionally
substituted with one to two R.sub.8, (i)
C.sub.1-8alkylS(O).sub.n--, optionally partially or fully
halogenated and optionally substituted with one to two R.sub.8,
(j)--N(R.sub.5)(R.sub.6), or (k) --C(O)NHR', wherein R' is R.sub.7,
pyridyl or --CH.sub.3; R.sub.2 is heteroaryl selected from the
group consisting of furanyl, thienyl, pyrrolyl, oxazolyl,
thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl,
oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridinyl,
pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, indolyl,
isoindolyl, benzofuranyl, benzothienyl, indazolyl, benzimidazolyl,
benzthiazolyl, benzoxazolyl, purinyl, quinolizinyl, quinolinyl,
isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl,
quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, acridinyl,
phenazinyl, phenothiazinyl and phenoxazinyl, substituted with one
to three R.sub.4; R.sub.3 is --OH or --H; R.sub.4 is chosen from,
C.sub.1-6alkoxy, hydroxyC.sub.1-6alkyl, halogen, --CN, --CO.sub.2H,
--CO.sub.2C.sub.1-6alkyl, --S(O)C.sub.1-6alkyl,
--S(O).sub.n-p-tolyl, --NO.sub.2, --OH, --CF.sub.3,
--N(R.sub.5)(R.sub.6), --NHC(O)NHC.sub.1-6alkyl,
--C(O)N(R.sub.5)(R.sub.6), and R.sub.9; R.sub.5 and R.sub.6 are
independently selected from H, C.sub.1-6alkyl,
--C(O)C.sub.1-6alkyl, --SO.sub.2C.sub.1-6alkyl, phenyl, pyridyl,
benzyl, piperidinyl, phenylethyl and (CH.sub.3).sub.3COC(O)--;
R.sub.7 is a phenyl group optionally substituted with one or two
groups selected from halogen, C.sub.1-6alkyl, --CN,
--CO.sub.2C.sub.1-6alkyl, --C(O)NR.sub.5R.sub.6,
--SO.sub.2NH.sub.2, --NO.sub.2, --OH, --NH.sub.2, --CF.sub.3 and
C.sub.1-6alkoxy, or R.sub.7 is C.sub.3-6cycloalkyl, --CH.sub.2OH,
naphthalene-2-yl, naphthalene-1-yl, pyridyl or thienyl; R.sub.8 is
selected from oxo, --OH, --NR.sub.4R.sub.5, --CO.sub.2H and
C.sub.1-6alkoxy; R.sub.9 is a heteroaryl selected from the group of
furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl,
pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl,
tetrazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl,
pyrazinyl, indolizinyl, indolyl, isoindolyl, benzofuranyl,
benzothienyl, indazolyl, benzimidazolyl, benzthiazolyl,
benzoxazolyl, purinyl, quinolizinyl, quinolinyl, isoquinolinyl,
cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl,
naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl,
phenothiazinyl and phenoxazinyl and methyl imidizolyl,
carbanomethylsulfanyl, methoxypiperidinyl, methoxypyridinyl,
bromopyridynyl and methoxypyrimidynyl; m is 0 or 1; n is 0, 1 or 2;
p is 0, 1, 2 or 3; Z is a bond or --O--CH.sub.2--; or a
pharmaceutically acceptable salt, ester, tautomer, individual
isomers, and mixtures of isomers thereof.
2. The method of claim 1 wherein said cancer disease is lymphoid
cancer.
3. The method of claim 1 wherein said cancer disease is myeloid-
and epithelial-derived malignancies.
4. The method of claim 1 wherein said cancer disease is
leukemia.
5. The method of claim 1 wherein said cancer disease is a
lymphomas.
6. The method of claim 1 wherein said cancer is gastric cancer,
colorectal cancer, lung cancer, and pancreatic cancer disease is
breast cancer.
7. The method of claim 1 wherein said cancer is breast cancer.
8. The method of claim 1 wherein said disease is gastric
cancer.
9. The method of claim 1 wherein said cancer is colorectal
cancer.
10. The method of claim 1 wherein said cancer is lung cancer.
11. The method of claim 1 wherein said cancer is pancreatic
cancer.
12. The method of claim 1 wherein said cancer is breast cancer.
Description
RELATED APPLICATIONS
[0001] This application is a Continuation of U.S. Ser. No.
11/500,237, filed Aug. 7, 2006, the entirety of which is
incorporated by reference herein, which is a continuation of U.S.
Ser. No. 11/002,828, filed Dec. 2, 2004 and US Serial number, which
claims priority to U.S. provisional application No. 60/527,522
filed on Dec. 5, 2003.
TECHNICAL FIELD OF THE INVENTION
[0002] This invention relates to substituted
3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds
useful as inhibitors of the kinase activity of the I.kappa.B kinase
(IKK) complex. The compounds are therefore useful in the treatment
of IKK-mediated diseases including autoimmune diseases,
inflammatory diseases and cancer. The invention also relates to
processes for preparing such compounds and pharmaceutical
compositions comprising them.
BACKGROUND OF THE INVENTION
[0003] NF-.kappa.B or nuclear factor .kappa.B is a transcription
factor that induces the expression of a large number of
pro-inflammatory and anti-apoptotic genes. These include cytokines
such as IL-1, IL-2, TNF-.alpha. and IL-6, chemokines including IL-8
and RANTES, as well as other pro-inflammatory molecules including
COX-2 and cell adhesion molecules such as ICAM-1, VCAM-1, and
E-selectin. The NF-.kappa.B family includes homo- and heterodimeric
transcription factors composed of members of the Rel family (see
for example P. A. Baeurle and D. Baltimore, Cell, 1996, 87, 13).
Under resting conditions, NF-.kappa.B is present in the cytosol of
cells as a complex with I.kappa.B. The I.kappa.B family of proteins
serve as inhibitors of NF-.kappa.B, interfering with the function
of its nuclear localization signal (see for example U. Siebenlist
et al., Ann. Rev. Cell Biol., 1994, 10, 405). Upon disruption of
the I.kappa.B-NF-.kappa.B complex following cell activation,
NF-.kappa.B translocates to the nucleus and activates gene
transcription. Disruption of the I.kappa.B-NF-.kappa.B complex and
subsequent activation of NF-.kappa.B is initiated by degradation of
I.kappa.B.
[0004] Upon cellular activation by a variety of pro-inflammatory
stimuli including IL-1, TNF-.alpha. and LPS (bacterial
lipopolysaccharide), two specific serine residues of I.kappa.B are
phosphorylated. Upon phosphorylation, I.kappa.B undergoes
polyubiquination and subsequent degradation by the 26S proteasome
(see for example V. J. Palombella et al., Cell, 1994, 78, 773),
freeing NF-.kappa.B to translocate to the nucleus. The
phosphorylation of I.kappa.B is carried out by the I.kappa.B
kinases (see for example a review by M. Karin and M. Delhase,
Seminars in Immunology, 2000, 12, 85). The traditional IKK complex
includes at least three subunits, IKK.alpha. (also called IKK-1),
IKK.beta. (or IKK-2) and IKK.gamma. (or NEMO), although other
relevant complexes involving IKK.alpha. and IKK.beta. may exist.
IKK.alpha. and IKK.beta. are both catalytic subunits while
IKK.gamma. is believed to be a regulatory subunit. Both IKK.alpha.
and IKK.beta. can phosphorylate I.kappa.B. For the purposes of this
document, the terms IKK or IKK complex refers to any complex that
has kinase activity derived from IKK.alpha. and/or IKK.beta.
subunits.
[0005] In vivo, activation of IKK occurs upon phosphorylation of
its catalytic subunit. Both IKK.alpha. and IKK.beta. can be
phosphorylated on serine residues, S177 and S181 of the activation
loop in the case of IKK.beta., and S176 and S180 of the activation
loop for IKK.alpha.. An IKK.beta. mutant having alanines in place
of serines at 177 and 181 prevented IKK.beta. phosphorylation and
subsequent activation of the IKK complex by TNF.alpha., IL-1 and
other upstream activators. These results support a key role for
IKK.beta. in phosphorylation of I.kappa.B following proinflammatory
stimulation.
[0006] Studies in which the NF-.kappa.B pathway has been inhibited
in cells and animals support the concept that inhibition of the
phosphorylation of I.kappa.B is a viable approach to treatment of
inflammatory, autoimmune and other diseases. In these studies,
NF-.kappa.B activation was prevented by expression of a
non-degradable version of the I.kappa.B protein. Expression of this
inhibitor in synovial cells derived from rheumatoid arthritis
patients reduced the expression of TNF-.alpha., IL-6, IL-1.beta.
and IL-8 while the anti-inflammatory molecules IL-10, IL-1ra and
IL-11 were not affected. Matrix metalloproteinases (MMP1 and MMP3)
were also down-regulated (J. Bonderson et al., Proc. Natl. Acad.
Sci. U.S.A., 1999, 96, 5668). Transgenic expression of the
I.kappa.B inhibitor in T cells caused a significant reduction in
the severity and onset of collagen-induced arthritis in mice (R.
Seetharaman et al., J. Immunol. 1999, 163, 1577). These experiments
indicate that suppression of NF-.kappa.B in the diseased joint
could reduce both the severity and progression of RA. In primary
intestinal epithelial cells, the NF-.kappa.B inhibitor blocked the
expression of IL-1, IL-8, iNOS and COX-2, mediators that are
up-regulated during the course of inflammatory bowel disease (C.
Jubin et al., J. Immunol., 1998, 160, 410). Expression of this
inhibitor in certain tumor cells enhances killing of these cells by
chemotherapeutic reagents (A. A. Beg and D. Baltimore, Science,
1996, 274, 782).
[0007] Analysis of biopsies from lungs of patients with chronic
obstructive pulmonary disease (COPD) found an increased expression
of NF-.kappa.B that correlated with disease severity (A. Di Stefano
et al., Eur. Resp. J., 2002, 1, 437). Inhibition of NF-.kappa.B
activation with inhibitors of IKK-.beta. was among the
anti-inflammatory approaches reported to be potentially useful in
the treatment of COPD (P. J. Barnes, Nature Rev. Drug Disc., 2002,
1, 437). Likewise, inhibition of NF-.kappa.B activity has been
mentioned as a therapeutic approach for asthma (A. Pahl and I.
Szelenyi, Infl. Res., 2002, 51, 273).
[0008] A recent review describes the essential role of inflammatory
mediators in the development cardiovascular disease. The
inflammatory mediators and the cells that they recruit are reported
to play a key role in the development of fatty streaks and plaques
that lead to atherosclerosis. In addition they are reported to play
a key role in subsequent degradation of the fibrous cap that forms
over the plaque, leading to rupture and clot formation. If the clot
grows large enough it can lead to myocardial infarction or stroke.
Thus, anti-inflammatory drugs that can inhibit the production of
these mediators and subsequent recruitment and activation of these
cells may be beneficial in treatment of these diseases (P. Libby,
Scientific American, 2002, 46).
[0009] A number of studies indicate that activation of NF-.kappa.B
also plays a key role in the pathogenesis and development of cancer
(see for example reviews by B. Haefner, Drug Disc. Today, 2002, 7,
653 and M. Karin et al., Nat. Rev. Cancer, 2002, 2, 301). Studies
have shown that cells in which NF-.kappa.B is constitutively active
are resistant to apoptosis. This can contribute to carcinogenesis
by preventing cell death in cells that have undergone chromosomal
changes or damage. In addition tumor cells with constitutively
active NF-.kappa.B are resistant to anti-cancer therapies including
chemotherapy and radiation. Further studies have linked activated
NF-.kappa.B to a variety of lymphoid-, myeloid- and
epithelial-derived malignancies including leukemia, lymphomas and
breast, gastric, colorectal, lung, and pancreatic cancers. Thus it
is suggested that inhibitors of NF-.kappa.B, including inhibitors
of IKK.alpha. and IKK.beta., may be useful either alone or in
combination with other anti-cancer therapies in treating
cancer.
[0010] Collectively, the studies described above provide support
that inhibition of NF-.kappa.B function through inhibition of IKK
may be a useful therapeutic approach to treatment of autoimmune and
inflammatory disease, cardiovascular disease and cancer.
[0011] Studies have also been done in mice with targeted disruption
of the IKK.beta. gene. Knockout of the IKK.beta. gene resulted in
embryonic lethality due to apoptosis of hepatocytes. However,
fibroblasts from the IKK.beta. knockouts did not undergo IKK and
NF-.kappa.B activation upon stimulation with IL-1 or TNF.alpha. (Q.
Li et al., Science, 1999, 284, 321), supporting a key role for
IKK.beta. in and NF-.kappa.B activation following inflammatory
stimuli.
[0012] A conditional knockout was generated by expressing a
liver-specific inducible dominant negative I.kappa.B.alpha.
transgene (I. Lavon et al., Nature Medicine, 2000, 6, 573). These
mice were viable with no signs of liver dysfunction even after one
year but they did have impaired immune function. This study
supports the idea that inhibition of IKK.beta. can result in immune
suppression without damage to the liver.
[0013] IKK.alpha. knock-out mice died shortly after birth and
displayed a variety of skeletal defects and skin abnormalities.
Fibroblast and thymocytes from these mice showed normal IKK
activation and I.kappa.B degradation in response to TNF.alpha.,
IL-1 or LPS (Y. Hu et al., Science, 1999, 284, 316; K. Takeda et
al., Science, 1999, 284, 313). Recent studies with knock-out and
knock-in mice have revealed distinct roles for IKK.alpha. in
development and cell signaling. In contrast to the studies with
IKK.alpha. knock-out mice, mice having a kinase inactive version of
IKK.alpha. knocked in are viable and fertile, indicating that the
perinatal lethality and abnormalities seen in the IKK.alpha.
knock-out mice are not due to the lack of kinase activity. However,
these mice do have defects in B cell maturation and development of
secondary lymphoid organs (U. Senftleben et al., Science, 2001,
293, 1495). This phenotype appears to be due to a defect in
processing of the NF-.kappa.B2/p100 protein to p52, the DNA binding
form of this member of the Rel family of transcription factors. In
turn, this leads to a defect in the activation of a subset of
NF-.kappa.B target genes in B cells. In addition, other studies
with these same mice have shown that IKK.alpha. kinase activity is
required for NF-.kappa.B activation in the mammary epithelium
during pregnancy (Cao, Y., et. al., Cell, 2001, 107, 763). This
pathway is specifically activated through the TNF receptor family
member RANK, requires phosphorylation of the canonical IKK
substrate I.kappa.B.alpha., and culminates in induction of the cell
cycle regulatory gene Cyclin D1.
[0014] These studies indicate that an inhibitor of IKK.alpha.
kinase activity may be useful in treating diseases associated with
inappropriate B cell activation such as lupus (O. T. Chan et al.,
Immunological Rev., 1999, 169, 107) and rheumatoid arthritis (A.
Gause and C. Borek, Biodrugs, 2001, 15, 73). In addition, an
inhibitor of IKK.alpha. may be useful in the treatment of breast
cancer since NF-.kappa.B is constitutively active in a number of
breast tumors and many of these tumors depend on Cyclin D1 for
proliferation.
[0015] Some inhibitors of IKK.beta. have been reported. For
example, WO 01/58890 and WO 03/037886 describe heteoaromatic
carboxamide derivatives as inhibitors of IKK.beta.. WO 01/68648
describes substituted .beta.-carbolines having IKK.beta. inhibiting
activity. Substituted indoles having IKK.beta. inhibitory activity
are reported in WO 01/30774. WO 01/00610 describes substituted
benzimidazoles having NF-.kappa.B inhibitory activity. Aspirin and
salicylate have been reported to bind to and inhibit IKK.beta. (M.
Yin et al., Nature, 1998, 396, 77).
[0016] Substituted thienopyridines having cell adhesion inhibiting
activity are reported in US 2001/0020030 A1 and A. O, Stewart et
al., J. Med. Chem., 2001, 44, 988. Thienopyridines exhibiting
gonadotropin releasing hormone antagonizing activity are reported
in U.S. Pat. No. 6,313,301. Substituted thienopyridines described
as telomerase inhibitors are disclosed in U.S. Pat. No.
5,656,638.
[0017] A number of 4,6-disubstituted
thieno[2,3-b]pyridine-2-carboxylic acid amides have been described
in the chemical literature. Examples include
3-amino-4,6-dimethyl-thieno[2,3-b]pyridine-2-carboxylic acid amide,
3-amino-6-methyl-thieno[2,3-b]pyridine-2,4-dicarboxylic acid
diamide,
3-amino-4-methyl-6-phenyl-thieno[2,3-b]-pyridine-2-carboxamide,
3-amino-6-methyl-4-phenyl-thieno[2,3-b]pyridine-2-carboxylic acid
amide,
3-amino-6-(4-bromo-phenyl)-4-methyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide,
3-amino-4-(4-bromo-phenyl)-6-methyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide, 3-amino-6-methyl-thieno[2,3-b]pyridine-2,4-dicarboxylic
acid 2-amide 4-butylamide,
3-amino-6-furan-2-yl-4-phenyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide,
3-amino-6-furan-2-yl-4-pyridin-3-yl-thieno[2,3-b]pyridine-2-carbox-
ylic acid amide,
3-amino-4-(4-chloro-phenyl)-6-phenyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide,
3-amino-4-(4-fluoro-phenyl)-6-furan-2-yl-thieno[2,3-b]pyridine-2-carboxyl-
ic acid amide,
3-amino-4-(4-chloro-phenyl)-6-furan-2-yl-thieno[2,3-b]pyridine-2-carboxyl-
ic acid amide,
3-amino-4-(4-bromo-phenyl)-6-furan-2-yl-thieno[2,3-b]pyridine-2-carboxyli-
c acid amide,
3-amino-4,6-bis-(4-chloro-phenyl)-thieno[2,3-b]pyridine-2-carboxylic
acid amide,
3-amino-6-naphth-2-yl-4-pyridin-3-yl-thieno[2,3-b]pyridine-2-carbo-
xylic acid amide,
3-amino-6-methyl-thieno[2,3-b]pyridine-2,4-dicarboxylic acid
2-amide 4-(2-hydroxyethyl)amide,
3-amino-6-methyl-4-piperidin-1-yl-thieno[2,3-b]-pyridine-2-carboxamide
and 3-amino-4-methyl-6-hydroxy-thieno[2,3-b]-pyridine-2-carboxamide
reported as intermediates for synthesis of tricyclic heterocycles
and evaluated for anti-allergic activity (G. Wagner et al.,
Pharmazie, 1990, 45, 102).
[0018] Other examples includes
3-amino-4,6-diphenyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
(A. M. Shestopalov et al., J. Org. Chem. USSR, (Engl. Transl.)
1984, 20, 1382),
3-amino-6-methyl-4-pyridin-4-yl-thieno[2,3-b]pyridine-2-carboxylic
acid amide and
3-amino-6-methyl-4-pyridin-3-yl-thieno[2,3-b]pyridine-2-carboxy-
lic acid amide (G. Wagner et al., Pharmazie, 1993, 48, 514),
3-amino-4-methoxymethyl-6-methyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide (E. I. Kaigorodova et al., Chem. Heterocycl. Compd.
(Engl. Transl.), 1996, 32, 1234),
3-amino-6-phenyl-4-thiophen-2-yl-thieno[2,3-b]pyridine-2-carboxylic
acid amide,
3-amino-4-furan-2-yl-6-methyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide,
3-amino-4-(4-chloro-phenyl)-6-methyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide and
3-amino-4-furan-2-yl-6-phenyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide (F. A. Attaby, Phosphorus, Sulfur, Silicon Relat. Elem.,
1998, 139, 1),
3-amino-6-(4-chloro-phenyl)-4-thiophen-2-yl-thieno[2,3-b]pyridine-2-c-
arboxylic acid amide (Y. Sharanin et al., J. Org. Chem. USSR,
(Engl. Transl.) 1996, 32, 1207),
3-amino-6-phenyl-4-pyridin-3-yl-thieno[2,3-b]pyridine-2-carboxylic
acid amide (A. Krauze, Eur. J. Med. Chem. Chim. Ther., 1999, 34,
301) and
3-amino-6-thiophen-2-yl-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxy-
lic acid amide (M. I. Abdel-Monem et al., Pharmazie, 2001, 56,
41).
[0019] In no case are these compounds described as having the
ability to inhibit IKK.alpha. or IKK.beta..
SUMMARY OF THE INVENTION
[0020] It is therefore an object of this invention to provide novel
compounds according to the following formula (I):
##STR00002##
wherein the variables R.sub.1, R.sub.2, R.sub.3 and Z are described
herein which inhibit IKK. It is a further object of the invention
to provide methods for treating diseases and pathological
conditions exacerbated by IKK such as, but not limited to
autoimmune diseases, inflammatory diseases and cancer. It is yet a
further object of the invention to provide novel processes for
preparation of the above-mentioned novel compounds.
DETAILED DESCRIPTION OF THE INVENTION
[0021] A first aspect of the invention comprises a method of
treating an inflammatory or autoimmune condition by administration
of certain novel and known molecules of the formula (I):
##STR00003##
wherein:
R.sub.1 is
[0022] (a) phenyl or heteroaryl selected from furanyl, thienyl,
pyridyl, pyrrolyl, imidazolyl and benzofuranyl, optionally
substituted with one to two R.sub.4, [0023] (b) heterocyclyl
selected from 1-piperidinyl, 1-piperazinyl, 1-pyrrolidinyl and
4-morpholinyl, optionally substituted with one to two groups
selected from C.sub.1-6alkyl, --CO.sub.2C.sub.1-5alkyl, phenyl,
benzyl, --OH and --C(O)heteroaryl, wherein the heteroaryl is
selected from furanyl, thienyl, pyridyl and pyrrolyl, [0024] (c)
R.sub.7(CH.sub.2).sub.mO--, [0025] (d) R.sub.7OCH.sub.2--, [0026]
(e) R.sub.7(CH.sub.2).sub.mNH--, [0027] (f)
R.sub.7(CH.sub.2).sub.p(CH.dbd.CH).sub.m--, [0028] (g)
C.sub.1-6alkyl, optionally partially of fully halogenated and
optionally substituted with one to two R.sub.8, [0029] (h)
C.sub.1-8 alkoxy, optionally partially of fully halogenated and
optionally substituted with one to two R.sub.8, [0030] (i)
C.sub.1-8alkylS(O).sub.n--, optionally partially of fully
halogenated and optionally substituted with one to two R.sub.8,
[0031] (j)--N(R.sub.5)(R.sub.6), or [0032] (k) --C(O)NHR', wherein
R' is R.sub.7, pyridyl or --CH.sub.3; R.sub.2 is heteroaryl
selected from the group consisting of furanyl, thienyl, pyrrolyl,
oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl,
isothiazolyl, oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl,
pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl,
indolyl, isoindolyl, benzofuranyl, benzothienyl, indazolyl,
benzimidazolyl, benzthiazolyl, benzoxazolyl, purinyl, quinolizinyl,
quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl,
quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, acridinyl,
phenazinyl, phenothiazinyl and phenoxazinyl, optionally substituted
with one to three R.sub.4;
R.sub.3 is --OH or --H;
[0033] R.sub.4 is chosen from C.sub.1-6alkyl, C.sub.1-6alkoxy,
hydroxyC.sub.1-6alkyl, halogen, --CN, --CO.sub.2H,
--CO.sub.2C.sub.1-6alkyl, --S(O).sub.nC.sub.1-6alkyl,
--S(O).sub.n-p-tolyl, --NO.sub.2, --OH, --CF.sub.3,
--N(R.sub.5)(R.sub.6), --NHC(O)NHC.sub.1-6alkyl,
--C(O)N(R.sub.5)(R.sub.6), phenyl optionally substituted with
halogen, C.sub.1-6alkyl, --CN or C.sub.1-6alkoxy, and heteroaryl
chosen from R.sub.9; R.sub.5 and R.sub.6 are independently selected
from H, C.sub.1-6alkyl, --C(O)C.sub.1-6alkyl,
--SO.sub.2C.sub.1-6alkyl, phenyl, pyridyl, benzyl, piperidinyl,
phenylethyl and (CH.sub.3).sub.3COC(O)--; R.sub.7 is a phenyl group
optionally substituted with one or two groups selected from
halogen, C.sub.1-6alkyl, --CN, --CO.sub.2C.sub.1-6alkyl,
--C(O)NR.sub.5R.sub.6, --SO.sub.2NH.sub.2, --NO.sub.2, --OH,
--NH.sub.2, --CF.sub.3 and C.sub.1-6alkoxy, or R.sub.7 is
C.sub.3-6cycloalkyl, --CH.sub.2OH, naphthalene-2-yl,
naphthalene-1-yl, pyridyl or thienyl; R.sub.8 is selected from oxo,
--OH, --NR.sub.4R.sub.5, --CO.sub.2H and C.sub.1-6alkoxy; R.sub.9
is a heteroaryl selected from the group of furanyl, thienyl,
pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl,
isothiazolyl, oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl,
pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl,
indolyl, isoindolyl, benzofuranyl, benzothienyl, indazolyl,
benzimidazolyl, benzthiazolyl, benzoxazolyl, purinyl, quinolizinyl,
quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl,
quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, acridinyl,
phenazinyl, phenothiazinyl and phenoxazinyl and methyl imidizolyl,
carbanomethylsulfanyl, methoxypiperidinyl, methoxypyridinyl,
bromopyridynyl and methoxypyrimidynyl; m is 0 or 1; n is 0, 1 or 2;
p is 0, 1, 2 or 3; Z is a bond or --O--CH.sub.2--; and
pharmaceutically acceptable salts, esters, tautomers, individual
isomers, and mixtures of isomers thereof.
[0034] In its second aspect, the invention provides novel compounds
of formula (I) as described above
wherein:
R.sub.1 is
(a) R.sub.7(CH.dbd.CH)--,
[0035] (b) C.sub.1-6alkyl, (c) --C.sub.2-3alkylOH,
(d) --CF.sub.3,
[0036] (e) --C.sub.1-6alkoxy, optionally partially or fully
halogenated (f) --OC.sub.2-3alkylOH, (g) --C.sub.1-6alkylthio, or
(h) --C(O)NHR', wherein R' is R.sub.6, pyridyl or --CH.sub.3;
R.sub.2 is heteroaryl selected from the group consisting of
furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl,
pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl,
thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl,
indolizinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl,
benzthiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl,
quinazolinyl, quinoxalinyl and naphthyridinyl, optionally
substituted with one to three R.sub.4;
R.sub.3 is --OH or --H;
[0037] R.sub.4 is chosen from C.sub.1-6alkyl, C.sub.1-6alkoxy,
hydroxyC.sub.1-6alkyl, halogen, --CN, --CO.sub.2H,
--CO.sub.2C.sub.1-6alkyl, --S(O).sub.nC.sub.1-6alkyl,
--S(O).sub.n-p-tolyl, --NO.sub.2, --OH, --CF.sub.3,
--N(R.sub.5)(R.sub.6), --NHC(O)NHC.sub.1-6alkyl,
--C(O)N(R.sub.5)(R.sub.6), phenyl optionally substituted with
halogen, C.sub.1-6alkyl, --CN or C.sub.1-6alkoxy, and heteroaryl
chosen from R.sub.9; R.sub.5 and R.sub.6 are independently selected
from H, C.sub.1-6alkyl, --C(O)C.sub.1-6alkyl,
--SO.sub.2C.sub.1-6alkyl, phenyl, pyridyl, benzyl, piperidinyl,
phenylethyl and (CH.sub.3).sub.3COC(O)--; R.sub.7 is a phenyl group
optionally substituted with one or two groups selected from
halogen, C.sub.1-6alkyl, --CN, --CO.sub.2C.sub.1-6alkyl,
--C(O)NR.sub.5R.sub.6, --SO.sub.2NH.sub.2, --NO.sub.2, --OH,
--NH.sub.2, --CF.sub.3 and C.sub.1-6alkoxy, or R.sub.7 is
C.sub.3-6cycloalkyl, --CH.sub.2OH, naphthalene-2-yl,
naphthalene-1-yl, pyridyl or thienyl; R.sub.9 is a heteroaryl
selected from the group of furanyl, thienyl, pyrrolyl, oxazolyl,
thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl,
oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridinyl,
pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, indolyl,
isoindolyl, benzofuranyl, benzothienyl, indazolyl, benzimidazolyl,
benzthiazolyl, benzoxazolyl, purinyl, quinolizinyl, quinolinyl,
isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl,
quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, acridinyl,
phenazinyl, phenothiazinyl and phenoxazinyl and methyl imidizolyl,
carbanomethylsulfanyl, methoxypiperidinyl, methoxypyridinyl,
bromopyridynyl and methoxypyrimidynyl; n is 0, 1 or 2; Z is a bond
or --O--CH.sub.2--; and pharmaceutically acceptable salts, esters,
tautomers, individual isomers, and mixtures of isomers thereof.
[0038] In another embodiment, there are provided novel compounds of
the formula (I) as described above and wherein:
R.sub.1 is
(a) R.sub.7(CH.dbd.CH)--,
[0039] (b) C.sub.1-6alkyl,
(c) --CF.sub.3,
[0040] (d) --C.sub.1-6alkoxy, optionally partially or fully
halogenated (e) --C.sub.1-6alkylthio, or (f) --C(O)NHR', wherein R'
is R.sub.6, pyridyl or --CH.sub.3; R.sub.2 is heteroaryl selected
from the group consisting of furanyl, thienyl, pyrrolyl, oxazolyl,
thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl,
oxadiazolyl, triazolyl, thiadiazolyl, pyridinyl, pyridazinyl,
pyrimidinyl, pyrazinyl, indolizinyl, indolyl, benzofuranyl,
benzothienyl, benzimidazolyl, benzthiazolyl, benzoxazolyl,
quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl and
naphthyridinyl, optionally substituted with one to three
R.sub.9;
R.sub.3 is --OH;
[0041] R.sub.4 is chosen from C.sub.1-6alkyl, C.sub.1-6alkoxy,
hydroxyC.sub.1-6alkyl, halogen, --CN, --CO.sub.2H,
--CO.sub.2C.sub.1-6alkyl, --S(O).sub.nC.sub.1-6alkyl,
--S(O).sub.n-p-tolyl, --NO.sub.2, --OH, --CF.sub.3,
--N(R.sub.5)(R.sub.6), and --C(O)N(R.sub.5)(R.sub.6); R.sub.5 and
R.sub.6 are independently selected from H, C.sub.1-6alkyl,
--C(O)C.sub.1-6alkyl, --SO.sub.2C.sub.1-6alkyl, phenyl, pyridyl,
benzyl, piperidinyl, phenylethyl and (CH.sub.3).sub.3COC(O)--;
R.sub.7 is a phenyl group optionally substituted with one or two
groups selected from halogen, C.sub.1-6alkyl, --CN,
--CO.sub.2C.sub.1-6alkyl, --C(O)NR.sub.5R.sub.6,
--SO.sub.2NH.sub.2, --NO.sub.2, --OH, --NH.sub.2, --CF.sub.3 and
C.sub.1-6alkoxy, or R.sub.7 is C.sub.3-6cycloalkyl, --CH.sub.2OH,
naphthalene-2-yl, naphthalene-1-yl, pyridyl or thienyl; n is 0, 1
or 2; Z is a bond or --O--CH.sub.2--; and pharmaceutically
acceptable salts, esters, tautomers, individual isomers, and
mixtures of isomers thereof.
[0042] In yet another embodiment of the invention there are
provided novel compounds of the formula (I) as described above and
wherein:
R.sub.1 is
(a) R.sub.7(CH.dbd.CH)--,
[0043] (b) C.sub.1-6alkyl,
(c) --CF.sub.3,
[0044] (d) --C.sub.1-6alkoxy, optionally partially or fully
halogenated (e) --C.sub.1-6alkylthio, or (f) --C(O)NHR', wherein R'
is R.sub.6, pyridyl or --CH.sub.3; R.sub.2 is heteroaryl selected
from the group consisting of, thienyl, thiazolyl, imidazolyl,
pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzothienyl,
benzimidazolyl, benzthiazolyl, quinolinyl and isoquinolinyl;
optionally substituted with one to three R.sub.4;
R.sub.3 is --OH;
[0045] R.sub.4 is chosen from C.sub.1-6alkyl, C.sub.1-6alkoxy,
hydroxyC.sub.1-6alkyl, halogen, --CN, --CO.sub.2H,
--CO.sub.2C.sub.1-6alkyl, --S(O).sub.nC.sub.1-6alkyl,
--S(O).sub.n-p-tolyl, --NO.sub.2, --OH, --CF.sub.3,
--N(R.sub.5)(R.sub.6), and --C(O)N(R.sub.5)(R.sub.6); R.sub.5 and
R.sub.6 are independently selected from H, C.sub.1-6alkyl,
--C(O)C.sub.1-6alkyl, --SO.sub.2C.sub.1-6alkyl, phenyl, pyridyl,
benzyl, piperidinyl and phenylethyl; R.sub.7 is a phenyl group
optionally substituted with one or two groups selected from
halogen, C.sub.1-6alkyl, --CN, --CO.sub.2C.sub.1-6alkyl,
--C(O)NR.sub.5R.sub.6, --SO.sub.2NH.sub.2, --NO.sub.2, --OH,
--NH.sub.2, --CF.sub.3 and C.sub.1-6alkoxy, or R.sub.7 is
C.sub.3-6cycloalkyl, --CH.sub.2OH, naphthalene-2-yl,
naphthalene-1-yl, pyridyl or thienyl; n is 0, 1 or 2; Z is a bond
or --O--CH.sub.2--; and pharmaceutically acceptable salts, esters,
tautomers, individual isomers, and mixtures of isomers thereof.
[0046] In still another embodiment of the invention there are
provided novel compounds of the formula (I) as described above and
wherein:
R.sub.1 is
(a) R.sub.7(CH.dbd.CH)--,
[0047] (b) C.sub.1-6alkyl,
(c) --CF.sub.3,
[0048] (d) --C.sub.1-6alkoxy, optionally partially or fully
halogenated (e) --C.sub.1-6alkylthio, or (f) --C(O)NHR', wherein R'
is R.sub.6, pyridyl or --CH.sub.3; R.sub.2 is heteroaryl selected
from the group consisting of, 3-thienyl, 2-thiazolyl, 2-imidazolyl,
2-, 3- and 4-pyridinyl, 4-pyrimidinyl, 2-pyrazinyl, 2-indolyl,
2-benzothienyl, 2-benzimidazolyl, 2-benzthiazolyl, 2-, 3-, 4- and
6-quinolinyl and 1- and 3-isoquinolinyl; optionally substituted
with one to three R.sub.4;
R.sub.3 is --OH;
[0049] R.sub.4 is chosen from C.sub.1-6alkyl, C.sub.1-6alkoxy,
hydroxyC.sub.1-6alkyl, halogen, --CN, --CO.sub.2H,
--CO.sub.2C.sub.1-6alkyl, --S(O).sub.nC.sub.1-6alkyl,
--S(O).sub.n-p-tolyl, --NO.sub.2, --OH, --CF.sub.3,
--N(R.sub.5)(R.sub.6), and --C(O)N(R.sub.5)(R.sub.6); R.sub.5 and
R.sub.6 are independently selected from H, C.sub.1-6alkyl,
--C(O)C.sub.1-6alkyl, --SO.sub.2C.sub.1-6alkyl, phenyl, pyridyl,
benzyl, piperidinyl and phenylethyl; R.sub.7 is a phenyl group
optionally substituted with one or two groups selected from
halogen, C.sub.1-6alkyl, --CN, --CO.sub.2C.sub.1-6alkyl,
--C(O)NR.sub.5R.sub.6, --SO.sub.2NH.sub.2, --NO.sub.2, --OH,
--NH.sub.2, --CF.sub.3 and C.sub.1-6alkoxy, or R.sub.7 is
C.sub.3-6cycloalkyl, --CH.sub.2OH, naphthalene-2-yl,
naphthalene-1-yl, pyridyl or thienyl; n is 0, 1 or 2; Z is a bond
or --O--CH.sub.2--; and pharmaceutically acceptable salts, esters,
tautomers, individual isomers, and mixtures of isomers thereof.
[0050] In a further embodiment of the invention there are provided
novel compounds of the formula (I) as described above and
wherein:
R.sub.1 is
[0051] (a) C.sub.1-3alkyl,
(b) --CF.sub.3, or
(c) --OCH.sub.2CF.sub.3
[0052] R.sub.2 is heteroaryl selected from the group consisting of,
3-thienyl, 2-thiazolyl, 2-imidazolyl, 2-, 3- and 4-pyridinyl,
4-pyrimidinyl, 2-pyrazinyl, 2-indolyl, 2-benzothienyl,
2-benzimidazolyl, 2-benzthiazolyl, 2-, 3-, 4- and 6-quinolinyl and
1- and 3-isoquinolinyl; optionally substituted with one to three
R.sub.4;
R.sub.3 is --OH;
[0053] R.sub.4 is chosen from C.sub.1-6alkyl, C.sub.1-6alkoxy,
hydroxyC.sub.1-6alkyl, halogen, --CN, --CO.sub.2H,
--CO.sub.2C.sub.1-6alkyl, --S(O).sub.nC.sub.1-6alkyl,
--S(O).sub.n-p-tolyl, --NO.sub.2, --OH, --CF.sub.3,
--N(R.sub.5)(R.sub.6), and --C(O)N(R.sub.5)(R.sub.6); R.sub.5 and
R.sub.6 are independently selected from H, C.sub.1-6alkyl,
--C(O)C.sub.1-6alkyl, --SO.sub.2C.sub.1-6alkyl, phenyl, pyridyl,
benzyl, piperidinyl and phenylethyl; n is 0, 1 or 2; Z is a bond;
and pharmaceutically acceptable salts, esters, tautomers,
individual isomers, and mixtures of isomers thereof.
[0054] In a further embodiment of the invention, there are provided
the following compounds:
TABLE-US-00001 Structure Name ##STR00004##
3-Amino-6-[4-(2-hydroxy-2-quinolin-4-yl-ethylamino)-piperidin-1-yl]-4-pro-
pyl-thieno[2,3-b]pyridine-2-carboxylic acid amide ##STR00005##
3-Amino-6-[4-(2-hydroxy-2-quinolin-2-yl-ethylamino)-piperidin-1-yl]-4-pro-
pyl-thieno[2,3-b]pyridine-2-carboxylic acid amide ##STR00006##
3-Amino-6-[4-(2-hydroxy-2-quinolin-3-yl-ethylamino)-piperidin-1-yl]-4-pro-
pyl-thieno[2,3-b]pyridine-2-carboxylic acid amide ##STR00007##
3-Amino-6-[4-(2-hydroxy-2-pyridin-2-yl-ethylamino)-piperidin-1-yl]-4-trif-
luoromethyl-thieno[2,3-b]pyridine-2-carboxylic acidamide
##STR00008##
3-Amino-6-[4-(2-hydroxy-2-pyridin-3-yl-ethylamino)-piperidin-1-yl]-4-trif-
luoromethyl-thieno[2,3-b]pyridine-2-carboxylic acidamide
##STR00009##
3-Amino-6-[4-(2-hydroxy-2-pyridin-4-yl-ethylamino)-piperidin-1-yl]-4-trif-
luoromethyl-thieno[2,3-b]pyridine-2-carboxylic acidamide
##STR00010##
3-Amino-6-[4-(2-hydroxy-2-quinolin-2-yl-ethylamino)-piperidin-1-yl]-4-tri-
fluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acidamide
##STR00011##
3-Amino-6-[4-(2-hydroxy-2-quinolin-3-yl-ethylamino)-piperidin-1-yl]-4-tri-
fluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acidamide
##STR00012##
3-Amino-6-[4-(2-hydroxy-2-isoquinolin-3-yl-ethylamino)-piperidin-1-yl]-4--
propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide ##STR00013##
3-Amino-6-[4-(2-hydroxy-2-isoquinolin-3-yl-ethylamino)-piperidin-1-yl]-4--
trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acidamide
##STR00014##
3-Amino-6-[4-(2-hydroxy-2-isoquinolin-1-yl-ethylamino)-piperidin-1-yl]-4--
propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide ##STR00015##
3-Amino-6-[4-(2-hydroxy-2-quinolin-4-yl-ethylamino)-piperidin-1-yl]-4-tri-
fluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acidamide
##STR00016##
3-Amino-6-[4-(2-hydroxy-2-isoquinolin-1-yl-ethylamino)-piperidin-1-yl]-4--
trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acidamide
##STR00017##
3-Amino-6-[4-(2-hydroxy-2-pyrazin-2-yl-ethylamino)-piperidin-1-yl]-4-prop-
yl-thieno[2,3-b]pyridine-2-carboxylic acid amide ##STR00018##
3-Amino-6-[4-(2-hydroxy-2-pyrazin-2-yl-ethylamino)-piperidin-1-yl]-4-trif-
luoromethyl-thieno[2,3-b]pyridine-2-carboxylic acidamide
##STR00019##
3-Amino-6-[4-(2-hydroxy-2-pyridin-2-yl-ethylamino)-piperidin-1-yl]-4-isop-
ropyl-thieno[2,3-b]pyridine-2-carboxylic acid amide ##STR00020##
3-Amino-4-cyclopropyl-6-[4-(2-hydroxy-2-pyridin-2-yl-ethylamino)-piperidi-
n-1-yl]-thieno[2,3-b]pyridine-2-carboxylic acid amide ##STR00021##
3-Amino-4-ethyl-6-[4-(2-hydroxy-2-pyridin-2-yl-ethylamino)-piperidin-1-yl-
]-thieno[2,3-b]pyridine-2-carboxylic acid amide ##STR00022##
3-Amino-6-[4-(2-hydroxy-2-pyridin-2-yl-ethylamino)-piperidin-1-yl]-4-(2,2-
,2-trifluoro-ethoxy)-thieno[2,3-b]pyridine-2-carboxylic acidamide
##STR00023##
3-Amino-6-[4-(2-hydroxy-2-thiophen-3-yl-ethylamino)-piperidin-1-yl]-4-pro-
pyl-thieno[2,3-b]pyridine-2-carboxylic acid amide ##STR00024##
3-Amino-6-[4-(2-hydroxy-2-thiazol-2-yl-ethylamino)-piperidin-1-yl]-4-prop-
yl-thieno[2,3-b]pyridine-2-carboxylic acid amide ##STR00025##
3-Amino-6-[4-(2-benzo[b]thiophen-2-yl-2-hydroxy-ethylamino)-piperidin-1-y-
l]-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
##STR00026##
3-Amino-6-[4-(2-benzo[b]thiophen-3-yl-2-hydroxy-ethylamino)-piperidin-1-y-
l]-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
##STR00027##
3-Amino-6-{4-[2-hydroxy-2-(1-methyl-1H-imidazol-2-yl)-ethylamino]-piperid-
in-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acidamide
##STR00028##
3-Amino-6-[4-(2-benzothiazol-2-yl-2-hydroxy-ethylamino)-piperidin-1-yl]-4-
-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide ##STR00029##
3-Amino-6-(4-{2-hydroxy-2-[1-(toluene-4-sulfonyl)-1H-indol-2-yl]-ethylami-
no}-piperidin-1-yl)-4-propyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide ##STR00030##
3-Amino-6-{4-[2-hydroxy-2-(1-methyl-1H-indol-2-yl)-ethylamino]-piperidin--
1-yl}-4-propyl-thieno [2,3-b]pyridine-2-carboxylic acidamide
##STR00031##
3-Amino-6-{4-[2-hydroxy-2-(1-methyl-1H-benzoimidazol-2-yl)-ethylamino]-pi-
peridin-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acidamide
##STR00032##
3-Amino-6-{4-[2-(1H-benzoimidazol-2-yl)-2-hydroxy-ethylamino]-piperidin-1-
-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
##STR00033##
3-Amino-6-{4-[2-hydroxy-2-(1H-imidazol-2-yl)-ethylamino]-piperidin-1-yl}--
4-propyl-thieno[2,3-b]pyridine-2-carboxylic acidamide ##STR00034##
3-Amino-6-{4-[2-(2,3-dichloro-pyridin-4-yl)-2-hydroxy-ethylamino]-piperid-
in-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
##STR00035##
3-Amino-6-(4-{2-hydroxy-2-[4-phenyl-1-(2-trimethylsilanyl-ethoxymethyl)-1-
H-imidazol-2-yl]-ethylamino}-piperidin-1-yl)-4-propyl-thieno[2,3-b]pyridin-
e-2-carboxylic acidamide ##STR00036##
3-Amino-6-[4-(2-hydroxy-2-pyridin-3-yl-ethylamino)-piperidin-1-yl]-4-prop-
yl-thieno[2,3-b]pyridine-2-carboxylic acid amide ##STR00037##
3-Amino-6-[4-(2-hydroxy-2-pyridin-2-yl-ethylamino)-piperidin-1-yl]-4-prop-
yl-thieno[2,3-b]pyridine-2-carboxylic acid amide ##STR00038##
3-Amino-6-[4-(2-hydroxy-2-pyridin-4-yl-ethylamino)-piperidin-1-yl]-4-prop-
yl-thieno[2,3-b]pyridine-2-carboxylic acid amide ##STR00039##
3-Amino-6-{4-[2-(5-cyano-pyridin-2-yl)-2-hydroxy-ethylamino]-piperidin-1--
yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acidamide
##STR00040##
3-Amino-6-{4-[2-hydroxy-2-(6-methyl-pyridin-2-yl)-ethylamino]-piperidin-1-
-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acidamide
##STR00041##
3-Amino-6-{4-[2-(5-benzylcarbamoyl-pyridin-2-yl)-2-hydroxy-ethylamino]-pi-
peridin-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid
amide ##STR00042##
3-Amino-6-{4-[2-(6-cyano-pyridin-2-yl)-2-hydroxy-ethylamino]-piperidin-1--
yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acidamide
##STR00043##
3-Amino-6-{4-[2-(6-carbamoyl-pyridin-2-yl)-2-hydroxy-ethylamino]-piperidi-
n-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
##STR00044##
3-Amino-6-{4-[2-hydroxy-2-(5-methyl-pyridin-2-yl)-ethylamino]-piperidin-1-
-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acidamide
##STR00045##
3-Amino-6-{4-[2-hydroxy-2-(1-methyl-1H-benzoimidazol-2-yl)-ethylamino]-pi-
peridin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide ##STR00046##
3-Amino-6-{4-[2-hydroxy-2-(2-methylsulfanyl-pyrimidin-4-yl)-ethylamino]-p-
iperidin-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic
acidamide ##STR00047##
3-Amino-6-{4-[2-hydroxy-2-(2-methylsulfanyl-pyrimidin-4-yl)-ethylamino]-p-
iperidin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide ##STR00048##
3-Amino-6-{4-[2-hydroxy-2-(6-methyl-pyridin-2-yl)-ethylamino]-piperidin-1-
-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acidamide
##STR00049##
3-Amino-6-[4-(2-hydroxy-2-quinolin-6-yl-ethylamino)-piperidin-1-yl]-4-pro-
pyl-thieno[2,3-b]pyridine-2-carboxylic acid amide ##STR00050##
3-Amino-6-[4-(2-hydroxy-2-quinolin-6-yl-ethylamino)-piperidin-1-yl]-4-tri-
fluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acidamide
##STR00051##
3-Amino-4-propyl-6-[4-(2-pyridin-2-yl-ethylamino)-piperidin-1-yl]-thieno[-
2,3-b]pyridine-2-carboxylic acidamide ##STR00052##
3-Amino-4-propyl-6-[4-(2-pyridin-3-yl-ethylamino)-piperidin-1-yl]-thieno[-
2,3-b]pyridine-2-carboxylic acidamide ##STR00053##
3-Amino-4-propyl-6-[4-(2-pyridin-4-yl-ethylamino)-piperidin-1-yl]-thieno[-
2,3-b]pyridine-2-carboxylic acidamide ##STR00054##
3-Amino-6-{4-[2-hydroxy-3-(pyridin-4-yloxy)-propylamino]-piperidin-1-yl}--
4-propyl-thieno[2,3-b]pyridine-2-carboxylic acidamide ##STR00055##
3-Amino-6-{4-[2-hydroxy-3-(quinolin-4-yloxy)-propylamino]-piperidin-1-yl}-
-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acidamide ##STR00056##
3-Amino-6-{4-[2-hydroxy-3-(isoquinolin-5-yloxy)-propylamino]-piperidin-1--
yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acidamide
##STR00057##
3-Amino-6-{4-[2-hydroxy-3-(quinolin-5-yloxy)-propylamino]-piperidin-1-yl}-
-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acidamide ##STR00058##
3-Amino-6-{4-[2-hydroxy-3-(quinolin-6-yloxy)-propylamino]-piperidin-1-yl}-
-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acidamide ##STR00059##
3-Amino-6-{4-[(S)-2-hydroxy-3-(quinolin-6-yloxy)-propylamino]-piperidin-1-
-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acidamide
##STR00060##
3-Amino-6-{4-[(R)-2-hydroxy-3-(quinolin-6-yloxy)-propylamino]-piperidin-1-
-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acidamide
##STR00061##
3-Amino-6-[4-((R)-2-hydroxy-2-pyridin-2-yl-ethylamino)-piperidin-1-yl]-4--
trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylicacid amide
##STR00062##
3-Amino-6-[4-((S)-2-hydroxy-2-pyridin-2-yl-ethylamino)-piperidin-1-yl]-4--
trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylicacid amide
##STR00063##
3-Amino-6-[4-(2-hydroxy-2-pyrimidin-5-yl-ethylamino)-piperidin-1-yl]-4-tr-
ifluoromethyl-thieno[2,3-b]pyridine-2-carboxylicacid amide
##STR00064##
3-Amino-6-{4-[(S)-2-(6-chloro-pyridin-2-yl)-2-hydroxy-ethylamino]-piperid-
in-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
##STR00065##
3-Amino-6-{4-[(R)-2-(6-chloro-pyridin-2-yl)-2-hydroxy-ethylamino]-piperid-
in-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
##STR00066##
3-Amino-6-{4-[(S)-2-(6-chloro-pyridin-2-yl)-2-hydroxy-ethylamino]-piperid-
in-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acidamide ##STR00067##
3-Amino-6-{4-[(R)-2-(6-chloro-pyridin-2-yl)-2-hydroxy-ethylamino]-piperid-
in-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acidamide ##STR00068##
3-Amino-6-{4-[(S)-2-hydroxy-2-(6-methyl-pyridin-2-yl)-ethylamino]-piperid-
in-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acidamide ##STR00069##
3-Amino-6-{4-[(R)-2-hydroxy-2-(6-methyl-pyridin-2-yl)-ethylamino]-piperid-
in-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acidamide ##STR00070##
3-Amino-6-{4-[2-(6-bromo-pyridin-2-yl)-2-hydroxy-ethylamino]-piperidin-1--
yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acidamide
##STR00071##
3-Amino-6-{4-[2-hydroxy-2-(6-hydroxy-pyridin-2-yl)-ethylamino]-piperidin--
1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acidamide ##STR00072##
3-Amino-6-{4-[2-hydroxy-2-(6-hydroxy-pyridin-2-yl)-ethylamino]-piperidin--
1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
##STR00073##
3-Amino-6-{4-[2-(6-chloro-pyridin-3-yl)-2-hydroxy-ethylamino]-piperidin-1-
-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acidamide
##STR00074##
3-Amino-6-{4-[2-hydroxy-2-(1-methyl-1H-imidazol-2-yl)-ethylamino]-piperid-
in-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acidamide ##STR00075##
3-Amino-6-{4-[2-hydroxy-2-(6-methoxy-pyridin-3-yl)-ethylamino]-piperidin--
1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acidamide ##STR00076##
3-Amino-6-{4-[2-(2-amino-thiazol-5-yl)-2-hydroxy-ethylamino]-piperidin-1--
yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acidamide
##STR00077##
3-Amino-6-{4-[2-hydroxy-2-(2-hydroxy-pyridin-4-yl)-ethylamino]-piperidin--
1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acidamide ##STR00078##
3-Amino-6-{4-[2-hydroxy-2-(2-methyl-3H-imidazol-4-yl)-ethylamino]-piperid-
in-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acidamide ##STR00079##
3-Amino-6-[4-(2-[3,3']bipyridinyl-6-yl-2-hydroxy-ethylamino)-piperidin-1--
yl]-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylicacid amide
##STR00080##
3-Amino-6-{4-[2-hydroxy-2-(5-quinolin-3-yl-pyridin-2-yl)-ethylamino]-pipe-
ridin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acidamide ##STR00081##
3-Amino-6-{4-[2-hydroxy-2-(5-phenyl-pyridin-2-yl)-ethylamino]-piperidin-1-
-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylicacid amide
##STR00082##
3-Amino-6-{4-[2-(5-bromo-pyridin-2-yl)-2-hydroxy-ethylamino]-piperidin-1--
yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acidamide
##STR00083##
3-Amino-6-{4-[2-(6'-dimethylamino-[3,3']bipyridinyl-6-yl)-2-hydroxy-ethyl-
amino]-piperidin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxyli-
cacid amide ##STR00084##
3-Amino-6-{4-[2-hydroxy-2-(5-pyrimidin-5-yl-pyridin-2-yl)-ethylamino]-pip-
eridin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acidamide ##STR00085##
3-Amino-6-[4-(2-[3,4']bipyridinyl-6-yl-2-hydroxy-ethylamino)-piperidin-1--
yl]-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylicacid amide
##STR00086##
3-Amino-6-{4-[2-hydroxy-2-(5-quinolin-8-yl-pyridin-2-yl)-ethylamino]-pipe-
ridin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acidamide ##STR00087##
3-Amino-6-{4-[2-hydroxy-2-(5-isoquinolin-4-yl-pyridin-2-yl)-ethylamino]-p-
iperidin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acidamide ##STR00088##
3-Amino-6-(4-{2-hydroxy-2-[5-(3-hydroxy-phenyl)-pyridin-2-yl]-ethylamino}-
-piperidin-1-yl)-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acidamide ##STR00089##
3-Amino-6-(4-{2-hydroxy-2-[5-(3-methanesulfonyl-phenyl)-pyridin-2-yl]-eth-
ylamino}-piperidin-1-yl)-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxy-
lic acidamide ##STR00090##
3-Amino-6-(4-{2-hydroxy-2-[5-(3-methanesulfonylamino-phenyl)-pyridin-2-yl-
]-ethylamino}-piperidin-1-yl)-4-trifluoromethyl-thieno[2,3-b]pyridine-2-ca-
rboxylicacid amide ##STR00091##
3-Amino-6-(4-{2-hydroxy-2-[5-(3-hydroxymethyl-phenyl)-pyridin-2-yl]-ethyl-
amino}-piperidin-1-yl)-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxyli-
c acidamide ##STR00092##
3-Amino-6-(4-{2-[5-(3-amino-phenyl)-pyridin-2-yl]-2-hydroxy-ethylamino}-p-
iperidin-1-yl)-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acidamide ##STR00093##
3-Amino-6-(4-{2-[5-(3-dimethylamino-phenyl)-pyridin-2-yl]-2-hydroxy-ethyl-
amino}-piperidin-1-yl)-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxyli-
cacid amide ##STR00094##
3-Amino-6-(4-{2-hydroxy-2-[5-(3-methylcarbamoyl-phenyl)-pyridin-2-yl]-eth-
ylamino}-piperidin-1-yl)-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxy-
licacid amide ##STR00095##
3-Amino-6-(4-{2-[5-(3-dimethylcarbamoyl-phenyl)-pyridin-2-yl]-2-hydroxy-e-
thylamino}-piperidin-1-yl)-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carbo-
xylic acidamide ##STR00096##
6-(4-{2-[5-(3-Acetylamino-phenyl)-pyridin-2-yl]-2-hydroxy-ethylamino}-pip-
eridin-1-yl)-3-amino-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylica-
cid amide ##STR00097##
3-Amino-6-{4-[2-(6'-amino-[3,3']bipyridinyl-6-yl)-2-hydroxy-ethylamino]-p-
iperidin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acidamide ##STR00098##
3-Amino-6-(4-{2-[5-(3-carbamoyl-phenyl)-pyridin-2-yl]-2-hydroxy-ethylamin-
o}-piperidin-1-yl)-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acidamide ##STR00099##
3-Amino-6-[4-(2-hydroxy-2-{5-[3-(morpholine-4-carbonyl)-phenyl]-pyridin-2-
-yl}-ethylamino)-piperidin-1-yl]-4-trifluoromethyl-thieno[2,3-b]pyridine-2-
-carboxylicacid amide ##STR00100##
3-Amino-6-(4-{2-hydroxy-2-[5-(2-methoxy-pyrimidin-5-yl)-pyridin-2-yl]-eth-
ylamino}-piperidin-1-yl)-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxy-
lic acidamide ##STR00101##
3-Amino-6-{4-[2-hydroxy-2-(6'-methoxy-[3,3']bipyridinyl-6-yl)-ethylamino]-
-piperidin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acidamide ##STR00102##
3-Amino-6-(4-{2-hydroxy-2-[5-(2-oxo-2,3-dihydro-1H-indol-6-yl)-pyridin-2--
yl]-ethylamino}-piperidin-1-yl)-4-trifluoromethyl-thieno[2,3-b]pyridine-2--
carboxylicacid amide ##STR00103##
3-Amino-6-(4-{2-hydroxy-2-[5-(2-oxo-2,3-dihydro-1H-indol-5-yl)-pyridin-2--
yl]-ethylamino}-piperidin-1-yl)-4-trifluoromethyl-thieno[2,3-b]pyridine-2--
carboxylicacid amide ##STR00104##
3-Amino-6-[4-(2-hydroxy-2-quinolin-8-yl-ethylamino)-piperidin-1-yl]-4-pro-
pyl-thieno[2,3-b]pyridine-2-carboxylicacid amide ##STR00105##
3-Amino-6-[4-(2-hydroxy-2-quinolin-8-yl-ethylamino)-piperidin-1-yl]-4-tri-
fluoromethyl-thieno[2,3-b]pyridine-2-carboxylicacid amide
##STR00106##
3-Amino-6-{4-[2-hydroxy-2-(2-phenyl-1H-benzoimidazol-5-yl)-ethylamino]-pi-
peridin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acidamide ##STR00107##
3-Amino-6-{4-[2-hydroxy-2-(2-isopropyl-1H-benzoimidazol-5-yl)-ethylamino]-
-piperidin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acidamide ##STR00108##
3-Amino-6-{4-[2-hydroxy-2-(2-phenyl-1H-benzoimidazol-5-yl)-ethylamino]-pi-
peridin-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid
amide ##STR00109##
3-Amino-6-{4-[2-hydroxy-2-(5-thiazol-2-yl-pyridin-2-yl)-ethylamino]-piper-
idin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acidamide ##STR00110##
3-Amino-6-{4-[2-(2-benzyl-1H-benzoimidazol-5-yl)-2-hydroxy-ethylamino]-pi-
peridin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acidamide ##STR00111##
3-Amino-6-(4-{2-hydroxy-2-[5-(3-methyl-3H-imidazol-4-yl)-pyridin-2-yl]-et-
hylamino}-piperidin-1-yl)-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carbox-
ylic acidamide ##STR00112##
3-Amino-6-{4-[2-(6-carbamoylmethylsulfanyl-pyridin-3-yl)-2-hydroxy-ethyla-
mino]-piperidin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic-
acid amide ##STR00113##
3-Amino-6-{4-[2-hydroxy-2-(6-phenyl-pyridin-3-yl)-ethylamino]-piperidin-1-
-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylicacid amide
##STR00114##
3-Amino-6-[4-(2-[2,3']bipyridinyl-5-yl-2-hydroxy-ethylamino)-piperidin-1--
yl]-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylicacid amide
##STR00115##
3-Amino-6-{4-[2-hydroxy-2-(6-pyrimidin-5-yl-pyridin-3-yl)-ethylamino]-pip-
eridin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acidamide ##STR00116##
3-Amino-6-(4-{2-hydroxy-2-[6-(2-methoxy-pyrimidin-5-yl)-pyridin-3-yl]-eth-
ylamino}-piperidin-1-yl)-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxy-
lic acidamide ##STR00117##
3-Amino-6-{4-[2-hydroxy-2-(6'-methoxy-[2,3']bipyridinyl-5-yl)-ethylamino]-
-piperidin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acidamide ##STR00118##
3-Amino-6-{4-[2-hydroxy-2-(6-quinolin-8-yl-pyridin-3-yl)-ethylamino]-pipe-
ridin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acidamide ##STR00119##
3-Amino-6-{4-[2-(6-bromo-pyridin-3-yl)-2-hydroxy-ethylamino]-piperidin-1--
yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acidamide
##STR00120##
3-Amino-6-{4-[2-hydroxy-2-(6-methoxy-pyridin-2-yl)-ethylamino]-piperidin--
1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acidamide
and pharmaceutically acceptable salts, esters, tautomers,
individual isomers, and mixtures of isomers thereof.
[0055] For all the compounds disclosed in this application, in the
event the nomenclature is in conflict with the structure, it shall
be understood that the compound is defined by the structure.
[0056] The invention includes pharmaceutically acceptable
derivatives of compounds of formula (I). A "pharmaceutically
acceptable derivative" refers to any pharmaceutically acceptable
acid, salt or ester of a compound of this invention, or any other
compound which, upon administration to a patient, is capable of
providing (directly or indirectly) a compound of this invention, a
pharmacologically active metabolite or pharmacologically active
residue thereof.
[0057] Pharmaceutically acceptable salts of the compounds of this
invention include those derived from pharmaceutically acceptable
inorganic and organic acids and bases. Examples of suitable acids
include hydrochloric, hydrobromic, sulfuric, nitric, perchloric,
fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic,
toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic,
formic, benzoic, malonic, naphthalene-2-sulfonic and
benzenesulfonic acids. Other acids, such as oxalic acid, while not
themselves pharmaceutically acceptable, may be employed in the
preparation of salts useful as intermediates in obtaining the
compounds of this invention and their pharmaceutically acceptable
acid addition salts. Salts derived from appropriate bases include
alkali metal (e.g., sodium), alkaline earth metal (e.g.,
magnesium), ammonium and N--(C.sub.1-C.sub.4 alkyl).sub.4.sup.+
salts.
[0058] In addition, the compounds of this invention include
prodrugs of compounds of the formula (I). Prodrugs include those
compounds that, upon simple transformation, are modified to produce
the compounds of the invention. Simple chemical transformations
include hydrolysis, oxidation and reduction which occur
enzymatically, metabolically or otherwise. Specifically, when a
prodrug of this invention is administered to a patient, the prodrug
may be transformed into a compound of formula (I), thereby
imparting the desired pharmacological effect.
[0059] Any compounds of this invention containing one or more
asymmetric carbon atoms may occur as racemates and racemic
mixtures, single enantiomers, diastereomeric mixtures and
individual diastereomers. All such isomeric forms of these
compounds are expressly included in the present invention. Each
stereogenic carbon may be in the R or S configuration, or a
combination of configurations.
[0060] Some of the compounds of the invention can exist in more
than one tautomeric form. The invention includes all such
tautomers.
[0061] The compounds of the invention are only those which are
contemplated to be `chemically stable` as will be appreciated by
those skilled in the art. For example, a compound which would have
a `dangling valency`, or a `carbanion` are not compounds
contemplated by the invention.
[0062] As used herein, the following abbreviations are used:
DMF is dimethylformamide; DMSO is dimethyl sulfoxide EtOAc is ethyl
acetate; EtOH is ethanol; HPLC is high-performance liquid
chromatography MeOH is methanol; THF is tetrahydrofuran; TLC is
thin layer chromatography
[0063] Terms not specifically defined herein should be given the
meanings that would be given to them by one of skill in the art in
light of the disclosure and the context. For example,
"C.sub.1-6alkoxy" is a C.sub.1-6alkyl with a terminal oxygen, such
as methoxy, ethoxy, propoxy, pentoxy and hexoxy. All alkyl,
alkylene or alkynyl groups shall be understood as being branched,
unbranched unless otherwise specified. Other more specific
definitions are as follows:
[0064] The term "alkyl" refers to a saturated aliphatic radical
containing from one to ten carbon atoms or a mono- or
polyunsaturated aliphatic hydrocarbon radical containing from two
to twelve carbon atoms unless otherwise stated. The mono- or
polyunsaturated aliphatic hydrocarbon radical contains at least one
double or triple bond, respectively. "Alkyl" refers to both
branched and unbranched alkyl groups. Examples of "alkyl" include
alkyl groups which are straight chain alkyl groups containing from
one to eight carbon atoms and branched alkyl groups containing from
three to ten carbon atoms. Other examples include lower alkyl
groups which are straight chain alkyl groups containing from one to
six carbon atoms and branched alkyl groups containing from three to
six carbon atoms. It should be understood that any combination term
using an "alk" or "alkyl" prefix refers to analogs according to the
above definition of "alkyl". For example, terms such as "alkoxy",
"alkylhio" refer to alkyl groups linked to a second group via an
oxygen or sulfur atom. "Alkanoyl" refers to an alkyl group linked
to a carbonyl group (C.dbd.O). Each alkyl or alkyl analog described
herein shall be understood to be optionally partially or fully
halogenated.
[0065] The term "cycloalkyl" refers to the cyclic analog of an
alkyl group, as defined above. Examples of cycloalkyl groups are
saturated or unsaturated nonaromatic cycloalkyl groups containing
from three to eight carbon atoms, and other examples include
cycloalkyl groups having three to six carbon atoms.
[0066] The term "heterocycloalkyl" refers to a stable 4-8 membered
(but preferably, 5 or 6 membered) monocyclic or 8-11 membered
bicyclic heterocycle radical which may be either saturated or
unsaturated, and is non-aromatic. Each heterocycle consists of
carbon atoms and from 1 to 4 heteroatoms chosen from nitrogen,
oxygen and sulfur. The heterocycle may be attached by any atom of
the cycle, which results in the creation of a stable structure.
Examples of "heterocycloalkyl" include radicals such as pyrrolinyl,
pyrrolidinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, morpholinyl,
thiomorpholinyl, piperazinyl, indolinyl, azetidinyl,
tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrofuranyl,
hexahydropyrimidinyl, hexahydropyridazinyl, dihydro-oxazolyl,
1,2-thiazinanyl-1,1-dioxide, 1,2,6-thiadiazinanyl-1,1-dioxide,
isothiazolidinyl-1,1-dioxide and imidazolidinyl-2,4-dione.
[0067] The term "halogen" refers to bromine, chlorine, fluorine or
iodine.
[0068] The term "aryl" shall be understood to mean a 6-12 membered
aromatic carbocycle, which can be a single ring or can be multiple
rings fused together or linked covalently. The term "aryl"
includes, for example, phenyl and naphthyl; other terms comprising
"aryl" will have the same definition for the aryl component,
examples of these moieties include: arylalkyl, aryloxy or
arylthio.
[0069] The term "heteroaryl" refers to a stable 5-8 membered (but
preferably, 5 or 6 membered) monocyclic or 8-11 membered bicyclic
aromatic heterocycle radical. Each heterocycle consists of carbon
atoms and from 1 to 4 heteroatoms chosen from nitrogen, oxygen and
sulfur. The heteroaryl group may be attached by any atom of the
ring which results in the creation of a stable structure. Examples
of "heteroaryl" include radicals such as furanyl, thienyl,
pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl,
isothiazolyl, oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl,
pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl,
indolyl, isoindolyl, benzofuranyl, benzothienyl, indazolyl,
benzimidazolyl, benzthiazolyl, benzoxazolyl, purinyl, quinolizinyl,
quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl,
quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, acridinyl,
phenazinyl, phenothiazinyl and phenoxazinyl.
[0070] The terms "optional" or "optionally" mean that the
subsequently described event or circumstances may or may not occur,
and that the description includes instances where the event or
circumstance occurs and instances in which it does not. For
example, "optionally substituted aryl" means that the aryl radical
may or may not be substituted and that the description includes
both substituted aryl radicals and aryl radicals having no
substitution.
[0071] The term "substituted" means that any one or more hydrogens
on an atom of a group or moiety, whether specifically designated or
not, is replaced with a selection from the indicated group of
substituents, provided that the atom's normal valency is not
exceeded and that the substitution results in a stable compound. If
a bond to a substituent is shown to cross the bond connecting two
atoms in a ring, then such substituent may be bonded to any atom on
the ring. When a substituent is listed without indicating the atom
via which such substituent is bonded to the rest of the compound,
then such substituent may be bonded via any atom in such
substituent. For example, when the substituent is piperazinyl,
piperidinyl, or tetrazolyl, unless specified otherwise, such
piperazinyl, piperidinyl, or tetrazolyl group may be bonded to the
rest of the compound of the invention via any atom in such
piperazinyl, piperidinyl, or tetrazolyl group. Generally, when any
substituent or group occurs more than one time in any constituent
or compound, its definition on each occurrence is independent of
its definition at every other occurrence. Thus, for example, if a
group is shown to be substituted with 0 to 2 R, then such group is
optionally substituted with up to two R groups and R at each
occurrence is selected independently from the defined list of
possible R. Such combinations of substituents and/or variables,
however, are permissible only if such combinations result in stable
compounds.
[0072] As used herein above and throughout this application,
"nitrogen" and "sulfur" include any oxidized form of nitrogen and
sulfur and the quaternized form of any basic nitrogen.
Methods of Therapeutic Use
[0073] In accordance with the invention, there are provided novel
methods of using the compounds of the formula (I). The compounds of
the invention are effective in inhibiting the activity of IKK.beta.
and/or IKK.alpha.. In particular, these compounds are useful in
blocking disease processes exacerbated by IKK.beta.-mediated
NF-.kappa.B activation and IKK.alpha. activation of B cell activity
or the cell cycle regulatory gene Cyclin D1. In blocking
NF-.kappa.B activation, compounds of the invention effectively
block transcription of genes encoding inflammatory cytokines
including IL-1, IL-2, IL-6, IL-8, TNF.alpha., chemokines including
IL-8 and RANTES as well as other pro-inflammatory molecules
including COX-2 and cell adhesion molecules such as ICAM-1, VCAM-1
and E-selectin. These mediators play a key role in the etiology of
inflammatory, autoimmune and cardiovascular disorders and cancer.
Preventing the production of these mediators is a desirable means
for treating these disorders. Thus there are provided methods for
treating these conditions using the compounds of the invention.
Such inflammatory and autoimmune conditions include but are not
limited to osteoarthritis, reperfusion injury, asthma, chronic
obstructive pulmonary disease (COPD), multiple sclerosis,
Guillain-Barre syndrome, Crohn's disease, ulcerative colitis,
psoriasis, graft versus host disease, systemic lupus erythematosus,
rheumatoid arthritis, Alzheimer's disease, toxic shock syndrome,
insulin-dependent diabetes mellitis, acute and chronic pain,
thermal injury, adult respiratory distress syndrome (ARDS),
multiple organ injury secondary to trauma, acute
glomerulonephritis, dermatoses with acute inflammatory components,
acute purulent meningitis or other central nervous system
disorders, Grave's disease, myasthenia gravis, scleroderma and
atopic dermatitis. Such cardiovascular disorders include but are
not limited to atherosclerosis, myocardial infarction and stroke.
Such cancers include but are not limited to lymphoid-, myeloid- and
epithelial-derived malignancies including leukemia, lymphomas and
breast, gastric, colorectal, lung, and pancreatic cancers. The
compounds of the invention can also be used to treat other
disorders associated with IKK activation of NF-.kappa.B unrelated
to those listed above or discussed in the Background of the
Invention. For example, the compounds of the invention may also be
useful in the treatment of cancer by enhancing the effectiveness of
chemotherapeutic agents. Therefore, the invention also provides
methods of treating inflammatory and autoimmune diseases, and other
diseases including cancer, comprising administering to a patient in
need of such treatment a pharmaceutically effect amount of a
compound according to the invention.
[0074] For therapeutic use, the compounds of the invention may be
administered in any conventional dosage form in any conventional
manner. Routes of administration include, but are not limited to,
intravenously, intramuscularly, subcutaneously, intrasynovially, by
infusion, sublingually, transdermally, orally, topically or by
inhalation. The preferred modes of administration are oral and
intravenous. Compositions comprising the compounds of the invention
for each of the aforementioned routes of administration will be
apparent to the skilled artisan. The invention also provides for
pharmaceutical compositions including a therapeutically effective
amount of the compounds according to the invention. Such
pharmaceutical compositions will include pharmaceutically
acceptable carriers and adjuvants as further described below.
[0075] The compounds of this invention may be administered alone or
in combination with adjuvants that enhance stability of the
inhibitors, facilitate administration of pharmaceutical
compositions containing them in certain embodiments, provide
increased dissolution or dispersion, increase inhibitory activity,
provide adjunct therapy, and the like, including other active
ingredients. Advantageously, such combination therapies utilize
lower dosages of the conventional therapeutics, thus avoiding
possible toxicity and adverse side effects incurred when those
agents are used as monotherapies. Compounds of the invention may be
physically combined with the conventional therapeutics or other
adjuvants into a single pharmaceutical composition. Advantageously,
the compounds may then be administered together in a single dosage
form. In some embodiments, the pharmaceutical compositions
comprising such combinations of compounds contain at least about
15%, but more preferably at least about 20%, of a compound of the
invention (w/w) or a combination thereof. Alternatively, the
compounds may be administered separately (either serially or in
parallel). Separate dosing allows for greater flexibility in the
dosing regime.
[0076] As mentioned above, dosage forms of the compounds of this
invention include pharmaceutically acceptable carriers and
adjuvants known to those of ordinary skill in the art. These
carriers and adjuvants include, for example, ion exchangers,
alumina, aluminum stearate, lecithin, serum proteins, buffer
substances, water, salts or electrolytes and cellulose-based
substances. Preferred dosage forms include, tablet, capsule,
caplet, liquid, solution, suspension, emulsion, lozenges, syrup,
reconstitutable powder, granule, suppository and transdermal patch.
Methods for preparing such dosage forms are known (see, for
example, H. C. Ansel and N. G. Popovish, Pharmaceutical Dosage
Forms and Drug Delivery Systems, 5th ed., Lea and Febiger (1990)).
Dosage levels and requirements are well-recognized in the art and
may be selected by those of ordinary skill in the art from
available methods and techniques suitable for a particular patient.
In some embodiments, dosage levels range from about 10-1000 mg/dose
for a 70 kg patient. Although one dose per day may be sufficient,
up to 5 doses per day may be given. For oral doses, up to 2000
mg/day may be required. As the skilled artisan will appreciate,
lower or higher doses may be required depending on particular
factors. For instance, specific dosage and treatment regimens will
depend on factors such as the patient's general health profile, the
severity and course of the patient's disorder or disposition
thereto, and the judgment of the treating physician.
General Synthetic Methods
[0077] The invention additionally provides for methods for making
the compounds of the formula (I). The compounds of the invention
may be prepared by the general methods and examples presented
below, and methods known to those of ordinary skill in the art.
Further reference in this regard may be made to U.S. application
Ser. No. 10/453,173, incorporated herein by reference in its
entirety. Optimum reaction conditions and reaction times may vary
depending on the particular reactants used. Unless otherwise
specified, solvents, temperatures, pressures, and other reaction
conditions may be readily selected by one of ordinary skill in the
art. Specific procedures are provided in the Synthetic Examples
section. Reaction progress may be monitored by conventional methods
such as thin layer chromatography (TLC). Intermediates and products
may be purified by methods known in the art, including column
chromatography, HPLC or recrystallization. Intermediates used in
the Schemes below may be readily prepared by methods known in the
art or described in the Synthetic Examples section below.
[0078] Compounds of formula I may be prepared by the procedure
described in Scheme I.
##STR00121##
[0079] As illustrated above, piperidone intermediate I may be
combined with amine intermediate III in a reductive amination
reaction to provide the desired compound of formula I. In another
procedure described in Scheme II, intermediate IV, bearing a
leaving group X, for example a halogen or trifluoromethylsulfonyl
group, is reacted with intermediate V in the presence of a suitable
base to provide the desired compound of formula I. In a related
procedure, V may be reacted with intermediate VI bearing two
leaving groups, such as halogen or trifluoromethanesulfonyl, to
provide VII. Subsequent reaction of VII with mercaptoacetamide in
the presence of a suitable base provides the desired compound of
formula I.
##STR00122##
SYNTHETIC EXAMPLES
Example 1
3-Amino-6-[4-(2-benzo[b]thiophen-2-yl-2-hydroxy-ethylamino)-piperidin-1-yl-
]-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
##STR00123##
[0081] Benzothiophene (671.5 mg, 5.00 mmol) was dissolved into 10
mL of dry THF and cooled to -78.degree. C. To this was added 1.7 M
t-BuLi (3.00 mL, 5.10 mmol) in a dropwise fashion. The reaction
stirred for 1 h. [(Methoxy-methyl-carbamoyl)-methyl]-carbamic acid
tert-butyl ester (545.6 mg, 2.50 mmol) was added in 2.5 mL of dry
THF in a dropwise fashion. The reaction was stirred for 2 h,
warming to -40.degree. C., then quenched with 15 mL of saturated
NH.sub.4Cl. The mixture was extracted with 2.times.20 mL of EtOAc
and the organic phase washed with 1.times.20 mL of brine. The
organic phase was dried with MgSO.sub.4, filtered and concentrated.
The residue was dissolved in CH.sub.2Cl.sub.2, applied to a
SiO.sub.2 column and purified (0-10% EtOAc/hexanes) to give 554 mg,
74.7%, of (2-benzo[b]thiophen-2-yl-2-oxo-ethyl)-carbamic acid
tert-butyl ester.
[0082] (2-Benzo[b]thiophen-2-yl-2-oxo-ethyl)-carbamic acid
tert-butyl ester (544 mg, 1.867 mmol) was dissolved into 3 mL of
EtOAc and 10 mL of 4.0 M HCl in dioxane was added. The mixture was
allowed to stir overnight with a white precipitate forming. The
precipitate was triturated with 3.times.10 mL of EtOAc and dried
under vacuum to give 400 mg, 94.7% of crude
2-amino-1-benzo[b]thiophen-2-yl-ethanone HCl salt. The material was
carried on without further purification.
[0083] The above 2-amino-1-benzo[b]thiophen-2-yl-ethanone HCl salt
(400.0 mg, 1.757 mmol) was dissolved into 3 mL of MeOH. The mixture
was cooled in a wet ice bath and NaBH.sub.4 (128.6 mg, 3.400 mmol)
was added in one portion, resulting in H.sub.2 formation. After 30
min, the mixture was concentrated to dryness on a rotary evaporator
to give an oil. The material was suspended in 6 mL
CH.sub.2Cl.sub.2/hexanes and concentrated to dryness. The cycle was
repeated until 2-amino-1-benzo[b]thiophen-2-yl-ethanol was obtained
as a gummy solid.
[0084] The above 2-amino-1-benzo[b]thiophen-2-yl-ethanol (57.9 mg,
0.300 mmol),
3-amino-6-(4-oxo-piperidin-1-yl)-4-propyl-thieno[2,3-b]pyridine-2--
carboxylic acid amide (50.0 mg, 0.15 mmol), MP-borohydride (100 mg)
and acetic acid (0.075 mL, 1.31 mmol) were mixed in a 2-dram vial
in THF (4 mL) and shaken at room temperature for 21 h overnight.
The reaction was filtered, and the borohydride resin was rinsed
with MeOH, and then filtered again. The combined filtrates were
concentrated in on a rotary evaporator to afford crude product. The
residue was dissolved into a minimal amount of MeOH, applied to a 1
mm prep plate (Merck) and eluted with 5% MeOH/CH.sub.2Cl.sub.2, 1%
NH.sub.3 to give 21.3 mg, 27.9% of the title compound. ES.sup.+
510.1 m/z (MH.sup.+).
[0085] The following compounds were also prepared by reaction of
the appropriate amine with
3-amino-6-(4-oxo-piperidin-1-yl)-4-propyl-thieno[2,3-b]pyridine-2-carboxy-
lic acid amide as described in Example 1:
[0086]
3-Amino-6-[4-(2-hydroxy-2-thiazol-2-yl-ethylamino)-piperidin-1-yl]--
4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide ES.sup.+
460.8 m/z (MH.sup.+) was prepared via the methods described in
example 1 and Scheme II.
[0087]
3-Amino-6-[4-(2-hydroxy-2-pyridin-3-yl-ethylamino)-piperidin-1-yl]--
4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide ES.sup.+
455.4 m/z (MH.sup.+). was prepared via the methods described in
example 1 and Scheme II.
[0088]
3-Amino-6-[4-(2-hydroxy-2-pyridin-2-yl-ethylamino)-piperidin-1-yl]--
4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide ES.sup.+ 455
m/z (MH.sup.+) was prepared via the methods described in example 1
and Scheme II.
[0089]
3-Amino-6-[4-(2-hydroxy-2-pyridin-4-yl-ethylamino)-piperidin-1-yl]--
4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide ES.sup.+
455.4 m/z (MH.sup.+) was prepared via the methods described in
example 1 and Scheme II.
[0090]
3-Amino-6-[4-(2-benzo[b]thiophen-3-yl-2-hydroxy-ethylamino)-piperid-
in-1-yl]-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
ES.sup.+ 510.6 m/z (MH.sup.+) was prepared via the methods
described in example 1 and Scheme II.
[0091]
3-Amino-6-{4-[2-hydroxy-2-(1-methyl-1H-imidazol-2-yl)-ethylamino]-p-
iperidin-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid
amide ES.sup.+ 458.7 m/z (MH.sup.+) was prepared via the methods
described in example 1 and Scheme II.
[0092]
3-Amino-6-[4-(2-benzothiazol-2-yl-2-hydroxy-ethylamino)-piperidin-1-
-yl]-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
ES.sup.+ 511.1 m/z (MH.sup.+) was prepared via the methods
described in example 1 and Scheme II.
[0093]
3-Amino-6-(4-{2-hydroxy-2-[1-(toluene-4-sulfonyl)-1H-indol-2-yl]-et-
hylamino}-piperidin-1-yl)-4-propyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide ES.sup.+ 647.0 m/z (MH.sup.+) was prepared via the
methods described in example 1 and Scheme II.
[0094]
3-Amino-6-{4-[2-hydroxy-2-(1-methyl-1H-indol-2-yl)-ethylamino]-pipe-
ridin-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
ES.sup.+ 507.7 m/z (MH.sup.+) was prepared via the methods
described in example 1 and Scheme II.
[0095]
3-Amino-6-{4-[2-hydroxy-2-(1-methyl-1H-benzoimidazol-2-yl)-ethylami-
no]-piperidin-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide ES.sup.+ 508.4 m/z (MH.sup.+) was prepared via the
methods described in example 1 and Scheme II.
[0096]
3-Amino-6-{4-[2-(1H-benzoimidazol-2-yl)-2-hydroxy-ethylamino]-piper-
idin-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
ES.sup.+ 494.1 m/z (MH.sup.+) was prepared via the methods
described in example 1 and Scheme II.
[0097]
3-Amino-6-{4-[2-hydroxy-2-(1H-imidazol-2-yl)-ethylamino]-piperidin--
1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
ES.sup.+ 444.4 m/z (MH.sup.+) was prepared via the methods
described in example 1 and Scheme II.
[0098]
3-Amino-6-{4-[2-(2,3-dichloro-pyridin-4-yl)-2-hydroxy-ethylamino]-p-
iperidin-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid
amide ES.sup.+ 523.1 m/z (MH.sup.+) was prepared via the methods
described in example 1 and Scheme II.
[0099]
3-Amino-6-{4-[2-hydroxy-2-(6-methyl-pyridin-2-yl)-ethylamino]-piper-
idin-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
ES.sup.+ 469.6 m/z (MH.sup.+) was prepared via the methods
described in example 1 and Scheme II.
[0100]
3-Amino-6-(4-{2-hydroxy-2-[4-phenyl-1-(2-trimethylsilanyl-ethoxymet-
hyl)-1H-imidazol-2-yl]-ethylamino}-piperidin-1-yl)-4-propyl-thieno[2,3-b]p-
yridine-2-carboxylic acid amide ES.sup.+ 650.8 m/z (MH.sup.+) was
prepared via the methods described in example 1 and Scheme II.
[0101]
3-Amino-6-{4-[2-hydroxy-2-(5-methyl-pyridin-2-yl)-ethylamino]-piper-
idin-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
ES.sup.+ 469.4 m/z (MH.sup.+) was prepared via the methods
described in example 1 and Scheme II.
[0102]
3-Amino-4-propyl-6-[4-(2-pyridin-2-yl-ethylamino)-piperidin-1-yl]-t-
hieno[2,3-b]pyridine-2-carboxylic acid amide ES.sup.+ 439.7 m/z
(MH.sup.+) was prepared via the methods described in example 1 and
Scheme II.
[0103]
3-Amino-4-propyl-6-[4-(2-pyridin-3-yl-ethylamino)-piperidin-1-yl]-t-
hieno[2,3-b]pyridine-2-carboxylic acid amide ES.sup.- 437.3 m/z
(M-1) was prepared via the methods described in example 1 and
Scheme II.
[0104]
3-Amino-4-propyl-6-[4-(2-pyridin-4-yl-ethylamino)-piperidin-1-yl]-t-
hieno[2,3-b]pyridine-2-carboxylic acid amide ES.sup.- 437.3 m/z
(M-1) was prepared via the methods described in example 1 and
Scheme II.
Example 2
3-Amino-6-[4-(2-hydroxy-2-thiophen-3-yl-ethylamino)-piperidin-1-yl]-4-prop-
yl-thieno[2,3-b]pyridine-2-carboxylic acid amide
##STR00124##
[0106] 3-Thiophene carboxaldehyde (0.438 mL, 5.000 mmol) was
dissolved into dry CH.sub.2Cl.sub.2 and placed under argon. To this
was added trimethylsilyl cyanide (0.933 mL, 7.000 mmol) and
triethylamine (0.070 mL, 0.500 mmol). The reaction mixture was
allowed to stir for 4 h. The mixture was concentrated on a rotary
evaporator to dryness to give
thiophen-3-yl-trimethylsilanyloxy-acetonitrile as a clear oil.
[0107] The above thiophen-3-yl-trimethylsilanyloxy-acetonitrile was
dissolved into 5 mL of dry THF. To this was added a 1.0 M solution
of BH.sub.3/THF (7.00 mL, 7.00 mmol). The reaction was stirred
overnight. The mixture was concentrated on a rotary evaporator. The
residue was dissolved into 10 mL of MeOH and concentrated on a
rotary evaporator with heating. This cycle was repeated 4 times.
The resulting crude amine was then carried on to the title compound
using the procedure described in Example 1. ES.sup.+ 460.2 m/z
(MH.sup.+).
Example 3
[0108]
3-Amino-6-{4-[2-(5-cyano-pyridin-2-yl)-2-hydroxy-ethylamino]-piperi-
din-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
was prepared by method 6, method 1,
[2-(5-Cyano-pyridin-2-yl)-2-hydroxy-ethyl]-carbamic acid tert-butyl
ester was prepared in the following manner.
##STR00125##
[0109] 2-(5-Bromo-pyridin-2-yl)-2-hydroxy-ethyl]-carbamic acid
tert-butyl ester (310 mg, 0.977 mmol), trisdibenzylidene
bispalladium (22.9 mg, 0.025 mmol),
1,1'-Bis(diphenylphosphino)ferrocene (DPPF) (27.1, 0.049 mmol) and
zinc cyanide (274 mg, 2.34 mmol) were placed in a microwave tube
and sealed with 3 mL of dry DMF. The tube was heated in the Smith
Synthesizer.TM. (Personal Chemistry) at 180.degree. C. for 10 min.
After cooling, the reaction mixture was diluted with 30 mL of
EtOAc. The organic phase was washed with 2.times.20 mL H.sub.2O and
1.times.20 mL of brine, dried with MgSO.sub.4, filtered and
concentrated. The residue was dissolved in CH.sub.2Cl.sub.2,
applied to a SiO.sub.2 column and purified (25-50% EtOAc/hexanes)
to give 152.1 mg, 52% of
[2-(5-cyano-pyridin-2-yl)-2-hydroxy-ethyl]-carbamic acid tert-butyl
ester.
[0110]
3-Amino-6-{4-[2-(5-cyano-pyridin-2-yl)-2-hydroxy-ethylamino]-piperi-
din-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
was prepared from the above amine using the procedure described in
Example 1. ES.sup.+ 480.3 m/z (MH.sup.+).
Example 4
3-Amino-6-{4-[2-(6-cyano-pyridin-2-yl)-2-hydroxy-ethylamino]-piperidin-1-y-
l}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
##STR00126##
[0112] 2-(6-Bromo-pyridin-2-yl)-2-hydroxy-ethyl]-carbamic acid
tert-butyl ester (447.0 mg, 1.504 mmol), trisdibenzylidene
bispalladium (33.9 mg, 0.037 mmol), DPPF (41.1, 0.075 mmol) and
zinc cyanide (423.0 mg, 3.61 mmol) were placed in a microwave tube
and sealed with 3 mL of dry DMF. The tube was heated in the Smith
Synthesizer.TM. (Personal Chemistry) at 180.degree. C. for 10 min.
After cooling, the reaction mixture was diluted with 30 mL of
EtOAc. The organic phase was washed with 2.times.20 mL H.sub.2O and
1.times.20 mL of brine. The organic phase was dried with
MgSO.sub.4, filtered and concentrated, the residue dissolved in
CH.sub.2Cl.sub.2 applied to a SiO.sub.2 column and purified (25-50%
EtOAc/hexanes) to give 147.5 mg, 37.2% of
[2-(6-cyano-pyridin-2-yl)-2-hydroxy-ethyl]-carbamic acid tert-butyl
ester and 126.0, 28% of
[2-(6-carbamoyl-pyridin-2-yl)-2-hydroxy-ethyl]-carbamic acid
tert-butyl ester.
[0113] [2-(6-Cyano-pyridin-2-yl)-2-hydroxy-ethyl]-carbamic acid
tert-butyl ester was deprotected by treatment with acid as
described in Example 1.
3-Amino-6-{4-[2-(6-cyano-pyridin-2-yl)-2-hydroxy-ethylamino]-piperidin-1--
yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide was
prepared via the procedure in Example 1. ES.sup.+ 480.3 m/z
(MH.sup.+).
[0114]
3-Amino-6-{4-[2-(6-carbamoyl-pyridin-2-yl)-2-hydroxy-ethylamino]-pi-
peridin-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid
amide was prepared by the deprotection of
[2-(6-carbamoyl-pyridin-2-yl)-2-hydroxy-ethyl]-carbamic acid
tert-butyl ester and further reaction by the procedure described in
Example 1. ES.sup.+ 498.3 m/z (MH.sup.+).
Example 5
3-Amino-6-{4-[2-(5-benzylcarbamoyl-pyridin-2-yl)-2-hydroxy-ethylamino]-pip-
eridin-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid
amide
##STR00127##
[0116] To 6-iodo-nicotinic acid methyl ester in 10 mL of dry THF at
-40.degree. C. was added a 2 M solution of i-propylmagnesium
chloride (4.33 mL, 8.60 mmol) in a dropwise fashion. The reaction
was allowed to stir for 1 h, warming to 0.degree. C. The flask was
cooled to -40.degree. C. and
[(methoxy-methyl-carbamoyl)-methyl]-carbamic acid tert-butyl ester
was added in one portion. The reaction mixture was allowed to warm
to room temperature over a 3 h period and stirred an additional h.
The reaction was quenched with saturated NH.sub.4Cl and 50 mL of
EtOAc was added. The organic phase was washed with 2.times.20 mL
H.sub.2O and 1.times.20 mL of brine, dried (MgSO.sub.4), filtered
and concentrated. The residue was dissolved in CH.sub.2Cl.sub.2,
applied to a SiO.sub.2 column and purified (0-20% EtOAc/hexanes) to
give 132.7 mg as a mixture of
6-(2-tert-butoxycarbonylamino-acetyl)-nicotinic acid methyl ester
to nicotinic acid methyl ester (3.2/.0.18).
[0117] 6-(2-tert-Butoxycarbonylamino-acetyl)-nicotinic acid methyl
ester (132.7 mg, 0.451 mmol) was dissolved into 3 mL of MeOH. To
this was added sodium borohydride (18.96 mg, 0.50 mmol) in one
portion. After 0.5 h, the reaction mixture was concentrated on a
rotary evaporator. The residue was dissolved into 20 mL of EtOAc.
The organic phase was washed with 2.times.20 mL NH.sub.4Cl and
1.times.20 mL of brine, dried (MgSO.sub.4) filtered and
concentrated to give 133 mg, 99.5% of
6-(2-tert-butoxycarbonylamino-1-hydroxy-ethyl)-nicotinic acid
methyl ester.
[0118] 6-(2-tert-Butoxycarbonylamino-1-hydroxy-ethyl)-nicotinic
acid methyl ester (137.3 mg, 0.450 mmol) was dissolved into 3 mL of
MeOH. To this was added LiOH monohydrate (56.5, 1.350 mmol). The
reaction stirred at room temperature overnight. The reaction
mixture was concentrated on a rotary evaporator, dissolved into 2
mL of water, and brought to pH 4 with AcOH. The mixture was
extracted into 3.times.10 mL of EtOAc and the organic fractions
combined. The organic phase was washed with 2.times.20 mL H.sub.2O
and 1.times.20 mL of brine, dried MgSO.sub.4, filtered and
concentrated to give 130 mg of
6-(2-tert-butoxycarbonylamino-1-hydroxy-ethyl)-nicotinic acid.
[0119] 6-(2-tert-Butoxycarbonylamino-1-hydroxy-ethyl)-nicotinic
acid (130 mg, 0.461 mmol), diisopropylethylamine (DIPEA) (0.426 mL,
2.44 mmol),
[(benzotriazol-1-yloxy)-dimethylamino-methylene]-dimethyl-ammonium
tetrafluoroborate (319 mg, 1.00 mmol), and benzyl amine (0.246 mL,
2.30 mmol) were dissolved into 3 mL of dry DMF and stirred
overnight. LC-MS indicated formation of the coupled product. The
mixture was diluted with 30 mL of EtOAc, the organic phase washed
with 2.times.20 mL H.sub.2O and 1.times.20 mL of brine, dried
(MgSO.sub.4) filtered and concentrated. The residue was dissolved
in CH.sub.2Cl.sub.2, applied to a SiO.sub.2 column and purified
(10-30% EtOAc/hexanes) to give 47.8, 27.9% of
[2-(5-benzylcarbamoyl-pyridin-2-yl)-2-hydroxy-ethyl]-carbamic acid
tert-butyl ester.
[0120]
[2-(5-Benzylcarbamoyl-pyridin-2-yl)-2-hydroxy-ethyl]-carbamic acid
tert-butyl ester (47.0 mg, 0.129 mmol) was dissolved into 2 mL of
EtOAc and 4.0 N HCl in dioxane (1.0 mL, 4 mmol) was added. The
reaction was allowed to stir overnight. The resulting precipitate
was triturated with 3.times.5 mL of THF and concentrated on a
rotary evaporator to dryness to give 43 mg of
6-(2-amino-1-hydroxy-ethyl)-N-benzyl-nicotinamide 2HCl.
[0121]
3-Amino-6-{4-[2-(5-benzylcarbamoyl-pyridin-2-yl)-2-hydroxy-ethylami-
no]-piperidin-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide was prepared from the above amine using the procedure
described in Example 1. ES.sup.+ 588.3 m/z (MH.sup.+).
Example 6
3-Amino-6-{4-[2-hydroxy-2-(2-methylsulfanyl-pyrimidin-4-yl)-ethylamino]-pi-
peridin-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid
amide
##STR00128##
[0123] 2-Amino-1-(2-methylsulfanyl-pyrimidin-4-yl)-ethanol
dihydrochloride salt (0.339 g, 1.83 mmol) was dissolved into a
minimum of MeOH and diluted with 10 mL of THF. To this was added
t-butyl-4-oxo-1-piperidinecarboxylate (0.478 g, 2.40 mmol), AcOH
(0.458 mL, 8.00 mmol) and sodium triacetoxyborohydride (1.696 g,
8.00 mmol) and the reaction was stirred overnight. LC-MS analysis
indicated complete consumption of the starting material. The
mixture was concentrated on a rotary evaporator, the residue
dissolved in CH.sub.2Cl.sub.2 and applied to a SiO.sub.2 column and
purified (0-10% MeOH/CH.sub.2Cl.sub.2) to give 511.0 mg, 57.8%
yield of
4-[2-hydroxy-2-(2-methylsulfanyl-pyrimidin-4-yl)-ethylamino]-piperidine-1-
-carboxylic acid tert-butyl ester.
[0124]
4-[2-Hydroxy-2-(2-methylsulfanyl-pyrimidin-4-yl)-ethylamino]-piperi-
dine-1-carboxylic acid tert-butyl ester (510.0 mg, 1.387 mmol) was
dissolved into 3 mL of EtOAc and 3 mL of 4.0 M HCl in dioxane was
added. The mixture was allowed to stir overnight with a white
precipitate forming. The precipitate was triturated with 3.times.10
mL of EtOAc and dried under vacuum to give 441.4 mg, 93.2% of crude
1-(2-methylsulfanyl-pyrimidin-4-yl)-2-(piperidin-4-ylamino)-ethanol
dihydrochloride salt. The material was carried on without further
purification.
[0125] The above amino alcohol dihydrochloride salt (268.36 mg,
0.700 mmol), DIPA (0.610 mL, 3.50 mmol) and triflate (200 mg, 0.586
mmol) were dissolved into 10 mL of dioxane and heated at 80.degree.
C. for 2 h. To the reaction mixture was added 5 mL of a 2.5 M
Na.sub.2CO.sub.3 solution. The mixture was refluxed overnight.
After cooling, the reaction mixture was diluted with 100 mL of
EtOAc. The organic phase was washed with 2.times.50 mL H.sub.2O and
1.times.50 mL of brine, dried Mg.sub.2SO4, filtered and
concentrated to give a tan residue which was triturated with
3.times.10 mL of EtOAc to give 153.2 mg, 52%, of the title
compound. ES.sup.+ 502.4 m/z (MH.sup.+).
Example 7
3-Amino-6-{4-[2-hydroxy-2-(1-methyl-1H-benzoimidazol-2-yl)-ethylamino]-pip-
eridin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide
##STR00129##
[0127] 2,6-Dichloro-4-trifluoromethyl-nicotinonitrile (277 mg, 1.15
mmol) was dissolved into 10 mL of absolute EtOH and cooled in a wet
ice bath. To this was added DIPEA (1.74 mL, 10 mmol) and
1-(1-methyl-1H-benzoimidazol-2-yl)-2-(piperidin-4-ylamino)-ethanol
dihydrochloride (400 mg, 1.15 mmol). The mixture was stirred for 2
h. LC-MS analysis indicated formation of the product. The reaction
mixture was concentrated on a rotary evaporator and the residue was
dissolved in CH.sub.2Cl.sub.2 and applied to a SiO.sub.2 column and
purified (0-10% MeOH/CH.sub.2Cl.sub.2) to give an oil, still
contaminated with DIPEA. Trituration with EtOAc gave 344 mg, 62.4%
of
6'-chloro-4-[2-hydroxy-2-(1-methyl-1H-benzoimidazol-2-yl)-ethylamino]-4'--
trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-carbonitrile.
[0128]
6'-Chloro-4-[2-hydroxy-2-(1-methyl-1H-benzoimidazol-2-yl)-ethylamin-
o]-4'-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-carbonitr-
ile (344.0 mg, 0.718) mmol was dissolved into 2 mL of dry DMF. To
this was added a 1.09 M MeOHic solution of mercaptoacetamide (1.00
mL, 1.09 mmol) and a 1 M solution of MeOHic NaOMe (2.87 mL, 2.87
mmol). The reaction mixture was heated at 60.degree. C. for 2 h.
LC-MS indicated complete conversion to the mercaptoacetamide
adduct. The reaction was then heated at 80.degree. C. overnight.
The reaction mixture was concentrated on a rotary evaporator with
heating to 70.degree. C. to give a dark orange oil. The oil was
dissolved into a minimal amount of MeOH, applied to a SIO.sub.2
column and eluted with 0-10% MeOH/CH.sub.2Cl.sub.2 and 0-10%
MeOH/CH2Cl2-1% NH3) to give 213.7 mg, 55.8%, of the title compound.
ES.sup.+ 534.3 m/z (MH+)
[0129] The following compounds were also prepared by using methods
described in the preceeding examples:
[0130]
3-Amino-6-{4-[2-hydroxy-2-(2-methylsulfanyl-pyrimidin-4-yl)-ethylam-
ino]-piperidin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide ES.sup.+ 528.5 m/z (MH.sup.+) was prepared via the
methods described in example 6 and Scheme II.
[0131]
3-Amino-6-{4-[2-hydroxy-2-(6-methyl-pyridin-2-yl)-ethylamino]-piper-
idin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide ES.sup.+ 495.3 m/z (MH.sup.+). was prepared via the
methods described in example 6 and Scheme II.
Example 8
3-Amino-6-[4-(2-hydroxy-2-quinolin-3-yl-ethylamino)-piperidin-1-yl]-4-prop-
yl-thieno[2,3-b]pyridine-2-carboxylic acid amide
##STR00130##
[0133] To a suspension of sodium hydride (60% in mineral oil, 480
mg, 12 mmol) in dry DMSO (5 mL) was added slowly a solution of
trimethylsulfonium iodide (2.66 g, 13 mmol) in 12 mL dry DMSO at
room temperature. After stirring for 5 min at room temperature, a
solution of 3-quinolinecarboxaldehyde (300 mg, 1.91 mmol) in 7 mL
DMSO was added. After addition of the aldehyde was complete, the
solution changed from colorless to yellow, then to brownish green.
Reaction progress was followed by LC-MS. After 1.5 h at room
temperature, the reaction mixture was quenched with ice water and
extracted with CH.sub.2Cl.sub.2 three times. The combined organic
extracts were washed twice with brine, dried (Na.sub.2SO.sub.4) and
filtered. The solvent was removed in vacuo to afford a brown oil
that was purified by flash column chromatography on SiO.sub.2 using
MeOH/CH.sub.2Cl.sub.2 mixtures as eluent providing 190 mg of clean
epoxide (1.11 mmol, 58% of theory) as a light yellow oil.
[0134] The quinoline epoxide obtained above (190 mg, 1.11 mmol) was
dissolved in 5 mL anhydrous CH.sub.3CN.
4-Amino-piperidine-1-tert-butyl-carboxylate (238 mg, 1.19 mmol) and
lithium perchlorate (127 mg, 1.19 mmol) were added. The resulting
suspension was diluted further with 10 mL CH.sub.3CN and stirred at
room temperature overnight, then in a 60.degree. C. oil bath for 41
h. The solvent was removed in vacuo and the residue was partitioned
between EtOAc and water. The aqueous layer was extracted once with
EtOAc and the combined organics were washed with brine, dried
(Na.sub.2SO.sub.4), filtered and concentrated in vacuo. The crude
material was purified by flash column chromatography on SiO.sub.2
using MeOH/CH.sub.2Cl.sub.2 mixtures as eluent to provide a
colorless oil, which was dissolved in 5 mL MeOH and treated with 5
mL 4N HCl in dioxane. After 2 h TLC showed starting material was
completely consumed. The solvent was removed in vacuo providing 265
mg of the dihydrochloride salt (0.77 mmol, 69% of theory) as a
light yellow foam.
[0135]
3-Amino-6-[4-(2-hydroxy-2-quinolin-3-yl-ethylamino)-piperidin-1-yl]-
-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide was
prepared by the method described in Example 6 (mp: 213-216.degree.
C., ES.sup.+ 505 m/z (MH.sup.+)).
[0136]
3-Amino-6-[4-(2-hydroxy-2-quinolin-4-yl-ethylamino)-piperidin-1-yl]-
-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide was
prepared via the methods described in example 8 and Scheme II
starting from 4-quinoline-carboxaldehyde. mp: 170-172.degree. C.,
ES.sup.+ 505 m/z (MH.sup.+).
[0137]
3-Amino-6-[4-(2-hydroxy-2-quinolin-2-yl-ethylamino)-piperidin-1-yl]-
-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide was
prepared via the methods described in example 8 and Scheme II
starting from 2-quinoline-carboxaldehyde. mp: 159-161.degree. C.,
ES.sup.+ 505 m/z (MH.sup.+).
Example 9
3-Amino-6-[4-(2-hydroxy-2-pyridin-3-yl-ethylamino)-piperidin-1-yl]-4-trifl-
uoromethyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
##STR00131##
[0139] In a round-bottom flask 2-(3-pyridyl)-2-hydroxy-1-ethylamine
(1.516 g, 10.97 mmol) was dispersed in 40 mL anhydrous
dichloroethane. To this suspension was added tert-butyl
4-oxo-piperidine-1-carboxylate (1.822 g, 9.14 mmol) and glacial
acetic acid (1.57 mL, 27.5 mmol). The mixture was stirred at room
temperature for 20 min. Then sodium triacetoxy-borohydride was
added (12.111 g, 57.14 mmol). The mixture was diluted with 10 mL
CH.sub.3CN and stirred at room temperature over two days.
[0140] The reaction mixture was quenched with saturated NaHCO.sub.3
solution and stirred for 30 min. It was then diluted with water and
extracted with CH.sub.2Cl.sub.2 three times. The combined organic
extracts were washed with brine, dried (MgSO.sub.4), filtered, and
the solvent was removed in vacuo. The residue was dissolved in
CH.sub.2Cl.sub.2 and loaded onto a flash silica gel chromatography
column. Purification using MeOH/CH.sub.2Cl.sub.2 mixtures as eluent
afforded 1.017 g of the Boc-protected piperidine as a yellow oil
(35% of theory).
[0141] The Boc-protected piperidine (1.017 g, 3.16 mmol) was
dissolved in a round-bottom flask in 30 mL MeOH. To this was added
10 mL 4N HCl in dioxane (40 mmol) and the mixture was stirred at
room temperature for 35 min. The progress of the reaction was
followed by TLC (10% MeOH/dichloromethane). The solvent was removed
in vacuo to afford 1.07 mg of a pink foam, which was used without
further purification.
[0142] The substituted 4-amino-piperidine dihydrochloride salt
obtained above (931 mg, 3.16 mmol) was dispersed in 40 mL EtOH at
0.degree. C. Added 2,6-dichloro-3-cyano-5-trifluoromethyl-pyridine
(763 mg, 3.16 mmol) and then, dropwise, added Hunig's base (2.21
mL, 12.66 mmol). The mixture was stirred at 0.degree. C. for 1 h.
TLC showed complete conversion. The solvent was removed in vacuo
and the residue was loaded onto a flash silica gel chromatography
column. Purification using MeOH/dichloromethane mixtures as eluent
afforded 709 mg of desired monochloro-pyridine as an orange foam
(53% of theory).
[0143] In a round-bottom flask, the chloro-pyridine obtained above
(709 mg, 1.67 mmol) was dissolved in 7 mL DMF. To this was added
2-mecaptoacetamide (10% in methanolic ammonia, 3.0 mL, 3.33 mmol)
and 6.7 mL 0.5 M NaOMe in MeOH (3.4 mmol). Stirred at room
temperature for 1 h, then added another 6.7 mL 0.5 M NaOMe in MeOH
(3.4 mmol) and stirred overnight in 60.degree. C. oil bath. Removed
solvent under high vacuum, added water and extracted with EtOAc
three times. Washed combined organics with brine, dried
(Na.sub.2SO.sub.4), filtered, and removed solvent in vacuo. The
residue was triturated in hot MeOH, and filtered through a Buchner
funnel. The crude product was purified by flash column
chromatography on SiO.sub.2 using MeOH/dichloromethane mixtures as
eluent. The title compound was obtained as a bright yellow solid,
305 mg (38% of theory). m.p.: 179-181.degree. C., ES.sup.+ 481 m/z
(MH.sup.+).
[0144]
3-Amino-6-[4-(2-hydroxy-2-pyridin-2-yl-ethylamino)-piperidin-1-yl]--
4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acid amide was
prepared via the methods described in example 9 and Scheme II
starting from 2-(2-pyridyl)-2-hydroxy-1-ethylamine. mp:
201-202.degree. C., ES.sup.+ 481 m/z (MH.sup.+).
[0145]
3-Amino-6-[4-(2-hydroxy-2-pyridin-4-yl-ethylamino)-piperidin-1-yl]--
4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acid amide was
prepared via the methods described in example 9 and Scheme II
starting from 2-(4-pyridyl)-2-hydroxy-1-ethylamine. mp:
217-220.degree. C., ES.sup.+ 481 m/z (MH.sup.+).
Example 10
3-Amino-6-[4-(2-hydroxy-2-quinolin-2-yl-ethylamino)-piperidin-1-yl]-4-trif-
luoromethyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
##STR00132##
[0147] To a suspension of sodium hydride (60% in mineral oil, 800
mg, 20.0 mmol) in dry DMSO (5 mL) was added slowly a solution of
trimethylsulfonium iodide (4.428 g, 21.7 mmol) in 21 mL dry DMSO at
room temperature. After stirring for 5 min, to the solution was
added a solution of 2-quinoline-carboxaldehyde (500 mg, 3.18 mmol)
in 7 mL DMSO. The color of the mixture changed from colorless to
yellow, then green. Reaction progress was followed by LC-MS and
after 40 min was quenched with ice water. Extraction of the aqueous
layer three times with CH.sub.2Cl.sub.2, and washing of the
combined organics with brine, afforded a green solution. This was
dried (Na.sub.2SO.sub.4), filtered, and the solvent was removed in
vacuo. The residue was dissolved in CH.sub.2Cl.sub.2 and purified
by flash column chromatography on SiO.sub.2 using
MeOH/dichloromethane mixtures as eluent. Thus were obtained 232 mg
of the desired epoxide, as a yellow oil (42.6% of theory).
[0148] In a round bottom flask containing 4 mL anhydrous CH.sub.3CN
was dissolved the 2-quinoline epoxide obtained above (232 mg, 1.36
mmol). The 4-amino-piperidine-1-tert-butyl-carboxylate (290 mg,
1.45 mmol) was then added, followed by LiClO.sub.4 (154 mg, 1.45
mmol). The addition is accompanied by a color change from yellow to
orange. The mixture was diluted with 4 mL more anhydrous
CH.sub.3CN, stirred in a 60.degree. C. oil bath overnight, then
diluted with water and extracted with EtOAc three times. The
combined organics were washed with brine, dried (Na.sub.2SO.sub.4),
and filtered. The solvent was removed in vacuo and the residue was
purified by flash column chromatography on SiO.sub.2 using
MeOH/dichloromethane mixtures as eluent. The pure substituted
amino-piperidine was obtained as a yellow oil, 368 mg (73% of
theory).
[0149] The Boc-protected piperidine obtained above (368 mg, 0.991
mmol) was dissolved in 10 mL MeOH. To this solution was added 5 mL
4N HCl in dioxane, and the mixture was left stirring at room
temperature overnight. Removal of the solvent in vacuo afforded 386
mg of the dihydro-chloride salt as a yellow foam, which was used in
the next step without purification.
[0150] The piperidine dihydrochloride salt obtained above (341 mg,
0.991 mmol) was dispersed in 20 mL absolute EtOH. The mixture was
cooled to 0.degree. C. and treated with the dichloro-pyridine (239
mg, 0.991 mmol), then Hunigs base was added dropwise to the
resulting solution. After 1 h the solvent was removed in vacuo to
yield a light yellow solid. Trituration in CH.sub.2Cl.sub.2,
followed by filtration afforded 414 mg of monochloro-pyridine as a
white solid (88% of theory).
[0151] In a round-bottom flask was dispersed in 7 mL DMSO the
monocholoro-pyridine from above (412 mg, 0.866 mmol). To this
mixture was added mercapto-acetamide (10% in methanolic ammonia,
0.95 mL, 1.04 mmol), followed by 2.1 mL 0.5 M sodium methoxide in
MeOH. The mixture was stirred at room temperature for 3 h, then
heated with stirring in a 60.degree. C. oil bath. Another portion
of sodium methoxide solution (2.1 mL) was added, and stirring was
continued at 60.degree. C. overnight. The solvent was removed under
high vacuum to afford a bright yellow solid which was triturated in
hot MeOH. Filtration through a vacuum Buchner funnel afforded 209
mg of pure, title compound (46% of theory). mp: 198-201.degree. C.,
ES.sup.+ 531 m/z (MH.sup.+).
[0152]
3-Amino-6-[4-(2-hydroxy-2-quinolin-3-yl-ethylamino)-piperidin-1-yl]-
-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
was prepared via the methods described in example 10 and Scheme II
starting from 3-quinoline-carboxaldehyde. ES.sup.+ 531 m/z
(MH.sup.+).
[0153]
3-Amino-6-[4-(2-hydroxy-2-quinolin-4-yl-ethylamino)-piperidin-1-yl]-
-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
was prepared via the methods described in example 10 and Scheme II
starting from 4-quinoline-carboxaldehyde. ES.sup.+ 531 m/z
(MH.sup.+).
Example 11
3-Amino-6-[4-(2-hydroxy-2-isoquinolin-3-yl-ethylamino)-piperidin-1-yl]-4-p-
ropyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
##STR00133##
[0155] Methyl 3-isoquinoline carboxylate (1.50 g, 8.01 mmol) was
placed in 60 mL anhydrous toluene and cooled to 0.degree. C. The
solution was treated dropwise with 1M DIBAL solution in toluene
(8.2 mL, 8.2 mmol). The solution gradually changed from colorless
to yellow and then orange during addition. After 2 h another 2 mL
1M DIBAL solution in toluene was added and the mixture was left
stirring another 1 h at 0-10.degree. C. The mixture was then
quenched with aqueous Na K tartrate solution, stirred 15 min then
diluted with brine and EtOAc. The layers were separated and the
aqueous was extracted twice with EtOAc. The combined organics were
washed with brine repeatedly (emulsion), dried (MgSO.sub.4),
filtered and the solvent was removed in vacuo. An orange oil was
thus obtained, which was purified by flash column chromatography on
SiO.sub.2 using CH.sub.2Cl.sub.2/MeOH eluent mixtures. The desired
isoquinoline carboxaldehyde was isolated as a yellow solid, 420 mg
(33% of theory).
[0156] To a suspension of sodium hydride (60% in mineral oil, 0.792
g, 19.8 mmol) in dry DMSO (18 mL) was added slowly a solution of
trimethylsulfonium iodide (4.3 g, 21.1 mmol) in 25 mL anhydrous
DMSO at room temperature. After stirring for 5 min, the
isoquinoline carboxaldehyde obtained above (520 mg, 3.31 mmol) was
added as a solution in 2 mL anhydrous DMSO. The mixture was left
stirring at room temperature for 1 h, then poured into ice water
and extracted three times with CH.sub.2Cl.sub.2. The combined
organic extracts were washed with brine and dried
(Na.sub.2SO.sub.4), filtered and the solvent was removed in vacuo.
The crude material was purified by column chromatography on
SiO.sub.2 using MeOH in dichloromethane as eluent. This afforded
319 mg of desired epoxide as a dark yellow oil.
[0157] The isoquinoline epoxide obtained above (319 mg, 1.86 mmol)
and 4-amino-piperidine-1-tert-butyl-carboxylate (373 mg, 1.86 mmol)
were combined in 7 mL anhydrous acetonitrile and treated with
lithium perchlorate solid (198 mg, 1.86 mmol). The mixture was left
stirring at room temperature for 1 day and at 60.degree. C.
overnight. The final color of the solution was orange. The mixture
was quenched with dilute NaHCO.sub.3 aqueous solution and extracted
three times with EtOAc. The combined organics were washed with
brine, dried (Na.sub.2SO.sub.4), filtered, and the solvent was
removed in vacuo to afford an orange foam. This crude material was
purified by flash column chromatography on SiO.sub.2 using mixtures
of dichloromethane and MeOH as eluent. The substituted
amino-Boc-protected piperidine (375 mg) was isolated as a yellow
foam. .sup.1H NMR was consistent with desired regioisomer.
[0158] The Boc-piperidine obtained above (375 mg, 1.01 mmol) was
dissolved in 30 mL MeOH and treated at room temperature with 4M HCl
in 1,4-dioxane (8.75 mL). The mixture was left stirring at room
temperature overnight. Removal of solvents in vacuo afforded the
dihydrochloride salt as a pale yellow foam, 439 mg. This was used
without purification in the next step.
[0159] The above isoquinolinyl-ethylamino-piperidine
dihydrochloride salt (160 mg, 0.52 mmol) was dispersed in 4 mL
anhydrous 1,4-dioxane. Triethylamine (0.73 mL, 5.2 mmol) was added
and the mixture was stirred 5 min. Pyridine-triflate was added (250
mg, 0.65 mmol) and the mixture was diluted with 4 mL more dioxane.
The reaction tube was placed in a 70.degree. C. oil bath and
stirred overnight. The reaction mixture was cooled and treated with
2M Na.sub.2CO.sub.3 aqueous solution. The tube was then sealed and
the 2-phase mixture stirred vigorously at 100.degree. C. for 7 h.
After cooling, water was added and the mixture was extracted with
EtOAc three times. The combined organics were washed with brine,
dried (Na.sub.2SO.sub.4), filtered, and the solvent was removed in
vacuo. A yellow-brown oil, 315 mg was obtained. This crude material
was purified by flash column chromatography on SiO.sub.2 using MeOH
in dichloromethane mixtures to afford 98 mg of a tan foam.
Trituration from hot MeOH afforded the title compound as a white
solid, 62 mg (24% of theory). mp: 213-215.degree. C. (dec),
ES.sup.+ 505 m/z (MH.sup.+).
[0160]
3-Amino-6-[4-(2-hydroxy-2-isoquinolin-3-yl-ethylamino)-piperidin-1--
yl]-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
was prepared via the methods described in example 11 and Scheme II
starting from methyl-3-isoquinoline carboxylate. mp:
169-172.degree. C., ES.sup.+ 531 m/z (MH.sup.+).
[0161]
3-Amino-6-[4-(2-hydroxy-2-isoquinolin-1-yl-ethylamino)-piperidin-1--
yl]-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide was
prepared via the methods described in example 11 and Scheme II
starting from methyl-1-isoquinoline carboxylate. mp:
<150.degree. C., ES.sup.+ 505 m/z (MH.sup.+).
[0162]
3-Amino-6-[4-(2-hydroxy-2-isoquinolin-1-yl-ethylamino)-piperidin-1--
yl]-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
was prepared via the methods described in example 8, example 3 and
Scheme II starting from methyl-1-isoquinoline carboxylate. ES.sup.+
531 m/z (MH.sup.+).
[0163]
3-Amino-6-[4-(2-hydroxy-2-quinolin-6-yl-ethylamino)-piperidin-1-yl]-
-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide was
prepared via the methods described in example 11 and Scheme II
starting from methyl-6-quinoline carboxylate. ES.sup.+ 505 m/z
(MH.sup.+).
[0164]
3-Amino-6-[4-(2-hydroxy-2-quinolin-6-yl-ethylamino)-piperidin-1-yl]-
-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
was prepared via the methods described in example 11 and Scheme II
starting from methyl-6-quinoline carboxylate. mp: 217-219.degree.
C., ES.sup.+ 531 m/z (MH.sup.+).
Example 12
3-Amino-6-[4-(2-hydroxy-2-pyrazin-2-yl-ethylamino)-piperidin-1-yl]-4-propy-
l-thieno[2,3-b]pyridine-2-carboxylic acid amide
##STR00134##
[0166] To a round bottom flask was added 2-pyrazinecarboxaldehyde
(770 mg, 7.12 mmol) in 10 mL of nitromethane, followed by the
addition of triethylamine (721 mg, 7.12 mmol). The reaction mixture
was stirred at room temperature for 1 h. The reaction mixture was
concentrated in vacuo. The residue was loaded onto a flash
chromatography column. The column was eluted with 0-5%
MeOH/CH.sub.2Cl.sub.2. The product fractions were collected and
concentrated to afford 1124 mg (93.3%) of
2-nitro-1-pyrazin-2-yl-ethanol. (TLC: Rf==0.2, 5%
MeOH/CH.sub.2Cl.sub.2, UV).
[0167] To a round bottom flask was added
2-nitro-1-pyrazin-2-yl-ethanol (1012 mg, 6 mmol), ammonium formate
(1886 mg, 30 mmol) and palladium 10% on activated carbon (220 mg)
in 40 mL of MeOH and 40 mL of THF. The reaction mixture was stirred
at room temperature for 18 h. The reaction mixture was filtered
through diatomaceous earth and concentrated in vacuo. The residue
was loaded onto a flash chromatography column. The column was
eluted with 0-5% 2M NH.sub.3 in MeOH/CH.sub.2Cl.sub.2. The product
fractions were collected and concentrated to afford 480 mg (57.7%)
of yellow solid 2-amino-1-pyrazin-2-yl-ethanol. (TLC: Rf=0.15, 5%
2M NH.sub.3 in MeOH/CH.sub.2Cl.sub.2, UV). MH.sup.+=140.3. The
above intermediate was carried on to the final compound using the
procedure described in Example 6. MH.sup.+=456.42
[0168]
3-Amino-6-[4-(2-hydroxy-2-pyrazin-2-yl-ethylamino)-piperidin-1-yl]--
4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acid amide was
prepared via the methods described in example 12 and Scheme II.
ES.sup.+ 482.41 m/z (MH.sup.+)
Example 13
Trifluoro-methanesulfonic acid
6-carbamoylmethylsulfanyl-5-cyano-4-cyclopropyl-pyridin-2-yl
ester
##STR00135##
[0170] To a solution of cyclopropyl acetylene (10.0 g, 148 mmol) in
50 mL of ethyl ether at -78.degree. C. under argon was added
methyllithium (1.4 M in ethyl ether, 107 mL, 150 mmol). This
solution was stirred at -78.degree. C. for 1 h. Methyl
chloroformate (12.0 mL, 154 mmol) was added. The reaction mixture
was warmed to room temperature in 2 h and was quenched with water.
The organic layer was separated. The aqueous layer was extracted
with ethyl ether (50 mL.times.3). The combined organic layer was
dried over sodium sulfate and evaporated to give
cyclopropyl-propynoic acid methyl ester as a yellow oil (13.25 g,
72%).
[0171] To a solution of cyclopropyl-propynoic acid methyl ester 1
(13.25 g, 0.107 mol) in 300 mL of absolute EtOH was added
morpholine (9.7 mL, 0.11 mol) at room temperature under argon. This
solution was heated at 45.degree. C. for 40 min.
2-Cyanothoioacetamide (11.36 g, 0.110 mol) was added. This mixture
was heated at 60.degree. C. for 1.5 h. A yellow precipitate was
formed. After standing at room temperature for 16 h,
3-cyano-4-cyclopropyl-6-oxo-1,6-dihydro-pyridine-2-thiol morpholine
salt (15.02 g, 50%) was collected by filtration, washed with EtOH
and then dried under vacuum at room temperature for 20 h.
[0172] 3-Cyano-4-cyclopropyl-6-oxo-1,6-dihydro-pyridine-2-thiol
morpholine salt (15.00 g, 53.69 mmol) was suspended in 15 mL of dry
DMF. 2-Bromoacetamide (7.74 g, 55.0 mmol) was added. This mixture
was stirred at room temperature for 30 min and quenched with water.
The resultant solid was collected by filtration, washed with water
and dried under high vacuum for 24 h to give
2-(3-cyano-4-cyclopropyl-6-oxo-1,6-dihydro-pyridin-2-ylsulfanyl)-acetamid-
e as a pale colored solid (13.22 g, 99%)
[0173]
2-(3-Cyano-4-cyclopropyl-6-oxo-1,6-dihydro-pyridin-2-ylsulfanyl)-ac-
etamide (13.22 g, 53.03 mmol) and
N-phenyltrifluoromethanesulfonimide (20.00 g, 55.42 mmol) was
suspended/dissolved in 100 mL of dichloromethane.
Diisopropylethylamine (10.00 mL, 56.83 mmol) was added. This
mixture was stirred at room temperature for 4 h. The title compound
was collected by filtration and washed with dichloromethane. Yield:
17.80 g 88%. (ES.sup.+ 382 m/z (MH.sup.+).
Example 14
Trifluoro-methanesulfonic acid
6-carbamoylmethylsulfanyl-5-cyano-4-ethyl-pyridin-2-yl ester
##STR00136##
[0175] To a solution of ethyl isobutyrate (12.0 g, 15.1 mmol) in 15
mL of dry DMF was added 2-cyanothioacetamide (7.76 g, 15.2 mmol)
followed by potassium tert-butoxide (9.00 g, 76.2 mmol). This
mixture was heated at 80.degree. C. under argon for 4 h, then
cooled to room temperature. 2-Bromoacetamide (10.6 g, 75.3 mmol)
was added. The resultant suspension was stirred at room temperature
for 30 min. Water was added.
2-(3-Cyano-4-isopropyl-6-oxo-1,6-dihydro-pyridin-2-ylsulfanyl)-acetamide
was collected by filtration and recrystallized from MeOH (4.62 g,
24%).
[0176]
2-(3-Cyano-4-isopropyl-6-oxo-1,6-dihydro-pyridin-2-ylsulfanyl)-acet-
amide (4.62 g, 18.4 mmol) and N-phenyltrifluoromethanesulfonimide
(7.00 g, 19.4 mmol) were suspended/dissolved in 100 mL of
dichloromethane. Diisopropylethylamine (4.00 mL, 22.7 mmol) was
added. This mixture was stirred at room temperature for 4 h.
Trifluoro-methanesulfonic acid
6-carbamoylmethylsulfanyl-5-cyano-4-isopropyl-pyridin-2-yl ester
was collected by filtration and washed with dichloromethane
providing 4.64 g (66%). (ES.sup.+ 384 m/z (MH.sup.+). The title
compound was prepared using a method analogous to that described in
Example 13.
Example 15
3-Amino-6-[4-(2-hydroxy-2-pyridin-2-yl-ethylamino)-piperidin-1-yl]-4-isopr-
opyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
##STR00137##
[0178] 2-Amino-1-pyridin-2-yl-ethanol (0.700 g, 5.07 mmol) and
N-boc-piperidone (1.20 g, 5.90 mmol) was dissolved in 5 mL of
1,2-dichloroethane. Glacial acetic acid (0.40 mL, 7.0 mmol) was
added followed by sodium triacetoxyborohydride (2.00 g, 8.97 mmol).
This mixture was stirred at room temperature under argon for 16 h.
The solvent was removed in vacuo and the residue was purified by
flash chromatography (silica gel 12 g, eluted with dichloromethane,
MeOH and ammonium hydroxide 100 to 95:4.9:0.1) to give
4-(2-hydroxy-2-pyridin-2-yl-ethylamino)-piperidine-1-carboxylic
acid tert-butyl ester as a brown oil (1.46 g, 90%).
[0179]
4-(2-Hydroxy-2-pyridin-2-yl-ethylamino)-piperidine-1-carboxylic
acid tert-butyl ester (1.46 g, 4.54 mmol) was dissolved in 5 mL of
MeOH. HCl in 1,4-dioxane (4.0 M, 5 mL, 20 mmol) was added. This
solution was stirred at room temperature for 40 min. The solvent
was removed in vacuo. The residue was triturated with ether to give
2-(Piperidin-4-ylamino)-1-pyridin-2-yl-ethanol dihydrochloride salt
as a brown solid (1.314 g, 88%)
[0180] The above solid (265 mg, 0.801 mmol) and
trifluoro-methanesulfonic acid
6-carbamoylmethylsulfanyl-5-cyano-4-isopropyl-pyridin-2-yl ester
(310 mg, 0.809 mmol) was dissolved/suspended in 10 mL of dioxane.
Triethylamine (0.56 mL, 4.0 mmol) was added. This reaction mixture
was heated at 80.degree. C. for 2 h. Potassium t-butoxide (230 mg,
1.95 mmol) was added. This reaction mixture was heated at
80.degree. C. for an additional 4 h. The solvent was removed in
vacuo and the residue was purified by silica gel flash
chromatography eluted with 0-5% ammonia/MeOH (0.1% ammonia) in
dichloromethane to give the title compound as a crystalline
product. Yield: 143 mg, 39%. ES.sup.+ 455 m/z (MH.sup.+).
[0181]
3-Amino-4-cyclopropyl-6-[4-(2-hydroxy-2-pyridin-2-yl-ethylamino)-pi-
peridin-1-yl]-thieno[2,3-b]pyridine-2-carboxylic acid amide was
prepared via the methods described in example 13 and Scheme II
(ES.sup.+ 453 m/z (MH.sup.+).
[0182]
3-Amino-4-ethyl-6-[4-(2-hydroxy-2-pyridin-2-yl-ethylamino)-piperidi-
n-1-yl]-thieno[2,3-b]pyridine-2-carboxylic acid amide was prepared
via the methods described in example 14 and Scheme II (ES.sup.+ 441
m/z (MH.sup.+).
Example 16
3-Amino-6-[4-(2-hydroxy-2-pyridin-2-yl-ethylamino)-piperidin-1-yl]-4-(2,2,-
2-trifluoro-ethoxy)-thieno[2,3-b]pyridine-2-carboxylic acid
amide
##STR00138## ##STR00139##
[0184] To a solution of 2,2-dimethyl-1,3-dioxane-4,6-dione (60.0 g,
416 mmol) in DMSO (150 mL) was added carbon disulfide (25 mL, 420
mmol) and triethylamine (116 mL, 832 mmol). The mixture was stirred
at room temperature for 1 h then cooled to 0.degree. C. and 52 mL
(830 mmol) of iodomethane was added. The reaction mixture was
allowed to slowly warm to room temperature and stirred for 15 h.
The mixture was decanted into an ice-H.sub.2O mixture and a solid
was precipitated by agitation of the solution. The solid was
collected by filtration, washed with a 1:1 mixture of petroleum
ether: Et.sub.2O, and dried under vacuum to provide 29.7 g (28.8%)
of
5-(bis-methylsulfanyl-methylene)-2,2-dimethyl-[1,3]dioxane-4,6-dione
as an orange solid.
[0185] To a solution of sodium ethoxide (40.0 mL, 123 mmol) in EtOH
(150 mL) was added cyanothioacetamide (12.5 g, 122 mmol). The
mixture was stirred at room temperature for 15 min then 30.0 g (121
mmol) of the above dione was added as a solution in EtOH (100 mL).
The suspension was heated to reflux for 15 h. The mixture was
cooled to room temperature and the solid was collected by
filtration. The material was wash with EtOH and dried under reduced
pressure to provide 12.5 (52.2%) of
2-mercapto-4-methylsulfanyl-6-oxo-1,6-dihydro-pyridine-3-carbonitrile
as a yellow solid.
[0186] To a solution of the above
2-mercapto-4-methylsulfanyl-6-oxo-1,6-dihydro-pyridine-3-carbonitrile
(12.5 g, 63.0 mmol) in DMF (300 mL), cooled to 0.degree. C., was
added sodium hydride (2.60 g, 65.0 mmol) as a 60% dispersion in
mineral oil. The mixture was stirred at 0.degree. C. for 30 min
then 2-bromoacetamide (8.80 g, 63.8 mmol) was added as a solid in
one portion. The mixture was allowed to slowly warm to room
temperature and stirred for 15 h. The mixture poured into
ice-H.sub.2O and stirred until all of the ice had melted, during
which time a solid precipitated from solution. The mixture was
acidified with 2N HCl then cooled to 0.degree. C. and the solid
collected by filtration. The material was washed with Et.sub.2O
followed by hexanes to provide 11.2 g (69.9%) of
2-(3-cyano-4-methylsulfanyl-6-oxo-1,6-dihydro-pyridin-2-ylsulfanyl)-aceta-
mide as a tan solid.
[0187] To a solution of
2-(3-cyano-4-methylsulfanyl-6-oxo-1,6-dihydro-pyridin-2-ylsulfanyl)-aceta-
mide (11.2 g, 44.1 mmol) in DMF (300 mL), cooled to 0.degree. C.,
was added sodium hydride (3.60 g, 90.0 mmol) as a 60% dispersion in
mineral oil. The mixture was stirred at 0.degree. C. for 30 min and
N-phenyltrifluoromethanesulfonimide was then (15.8 g, 44.2 mmol)
added as a solution in DMF (100 mL). The mixture was allowed to
slowly warm to room temperature and stirred for 15 h. The mixture
was poured into H.sub.2O which caused a solid to precipitate from
solution. The solid was collected by filtration, washed with
H.sub.2O and dried under reduced pressure to provide 8.95 (52.4%)
of trifluoro-methanesulfonic acid
3-amino-2-carbamoyl-4-methylsulfanyl-thieno[2,3-b]pyridin-6-yl
ester as a yellow powder.
[0188] To a suspension of the above trifluoro-methanesulfonic acid
3-amino-2-carbamoyl-4-methylsulfanyl-thieno[2,3-b]pyridin-6-yl
ester (8.95 g, 23.1 mmol) in a 1:1 mixture of H.sub.2O and MeOH
(200 mL), cooled to 0.degree. C., was added oxzone (17.0 g, 27.7
mmol) as a solid in one portion. The reaction mixture was allowed
to slowly warm to room temperature and stirred for 6 h. LCMS
indicated the presence of the desired product with a trace that
exhibited a peak at mass 404.08 [M+H].sup.+. The yellow solid was
collected by filtration and washed with H.sub.2O. The residue was
purified by washing with EtOAc and drying under reduced pressure to
provide 3.00 g (32.2%) of trifluoro-methanesulfonic acid
3-amino-2-carbamoyl-4-methanesulfinyl-thieno[2,3-b]pyridin-6-yl
ester as a yellow powder.
[0189] To a solution of trifluoro-methanesulfonic acid
3-amino-2-carbamoyl-4-methanesulfinyl-thieno[2,3-b]pyridin-6-yl
ester (3.00 g, 7.44 mmol) in DMF (100 mL) was added
1,4-dioxa-8-azaspiro[4,5]-decane (2.20 g, 15.4 mmol). The mixture
was heated to 70.degree. C. for 1 h. The mixture was cooled to room
temperature, diluted with H.sub.2O, and washed with
CH.sub.2Cl.sub.2. The combined organic phase was dried over
anhydrous Na.sub.2SO.sub.4 and concentrated under reduced pressure.
The residue was purified by flash silica gel chromatography to
provide 1.25 g (42.2%) of
3-amino-6-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-4-methanesulfinyl-thieno[2-
,3-b]pyridine-2-carboxylic acid amide as a yellow solid.
[0190] To 30 mL of 2,2,2-trifluoroethanol cooled to 0.degree. C.
was added sodium metal (0.60 g, 15 mmol), cut fresh and washed in
hexanes, in small portions. The mixture was allowed to warm up to
room temperature and let stir until all of the sodium metal had
reacted. To the mixture was added
3-amino-6-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-4-methanesulfinyl-thieno[2-
,3-b]pyridine-2-carboxylic acid amide (1.30 g, 3.28 mmol) as a
solid in one portion. The mixture was heated to 70.degree. C. for
15 h. The mixture was cooled to room temperature and diluted with
H.sub.2O. The mixture was washed with CH.sub.2Cl.sub.2 and the
combined organic phase was dried over anhydrous Na.sub.2SO.sub.4
and concentrated under reduced pressure. The residue was purified
by flash silica gel chromatography to provide 0.940 g of
3-amino-6-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-4-(2,2,2-trifluoro-ethoxy)-
-thieno[2,3-b]pyridine-2-carboxylic acid amide as a white
powder.
[0191] A solution of
3-amino-6-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-4-(2,2,2-trifluoro-ethoxy)-
-thieno[2,3-b]pyridine-2-carboxylic acid amide as a white powder
(0.940 g, 2.17 mmol) in a 4:1 mixture of acetic acid: H.sub.2O (20
mL) was heated to 80.degree. C. for 4 h then cooled to room
temperature and made basic by the addition of a saturated aqueous
solution of NaHCO.sub.3 which caused a solid to precipitate from
solution. The solid was collected by filtration and dried under
reduced pressure to provide 0.680 g (80.5%) of
3-amino-6-(4-oxo-piperidin-1-yl)-4-(2,2,2-trifluoro-ethoxy)-thieno[2,3-b]-
pyridine-2-carboxylic acid amide as a clear oil.
[0192] The title compound was prepared from the above intermediate
using a procedure analogous to that described in Example 1.
ES.sup.+ 511.22 m/z (MH.sup.+)
Example 17
3-Amino-6-{4-[2-hydroxy-3-(pyridin-4-yloxy)-propylamino]-piperidin-1-yl}-4-
-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
##STR00140##
[0194] To a round bottom flask was added 4-hydroxypyridine (250 mg,
2.63 mmol), glycidol (194.74 mg, 2.63 mmol) and triphenylphosphine
(758.45 mg, 2.89 mmol) in 20 mL of dry THF, followed by the
addition of diethyl azodicarboxylate (503.6 mg, 2.89 mmol). The
reaction mixture was stirred at room temperature for 18 h. The
reaction mixture was concentrated in vacuo. The residue was diluted
with CH.sub.2Cl.sub.2. The organic phase was washed with saturated
NaHCO.sub.3 and brine. The organic phase was dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated. The residue was loaded
to a flash chromatography column. The column was eluted with 0-5%
MeOH/CH.sub.2Cl.sub.2. The product fractions were collected and
concentrated to afford 80 mg (20.1%) of 4-oxiranylmethoxy-pyridine.
(TLC: Rf=0.4, 5% MeOH/CH.sub.2Cl.sub.2, UV). MH.sup.+=152.31.
[0195] To a sealed tube was added 4-oxiranylmethoxy-pyridine (80
mg, 0.529 mmol) in 4 mL of DMF, followed by the addition of
4-amino-1-N-boc-piperidine (148 mg, 0.739 mmol). The reaction
mixture was stirred at 80.degree. C. for 48 h. The reaction mixture
was concentrated in vacuo. The residue was loaded to a flash
chromatography column. The column was eluted with 0-5% 2M NH.sub.3
in MeOH/CH.sub.2Cl.sub.2. The product fractions were collected and
concentrated to afford 68 mg (36.6%) of
4-[2-hydroxy-3-(pyridin-4-yloxy)-propylamino]-piperidine-1-carboxylic
acid tert-butyl ester as a light brown oil. (TLC: Rf=0.15, 5% 2M
NH.sub.3 in MeOH/CH.sub.2Cl.sub.2, UV). ES.sup.+ 352.43 m/z
(MH.sup.+)
[0196] To a round bottom flask was added
4-[2-hydroxy-3-(pyridin-4-yloxy)-propylamino]-piperidine-1-carboxylic
acid tert-butyl ester (68 mg, 0.194 mmol) in 5 mL of HCl (4.0 M in
1,4-dioxane) and 5 mL of MeOH. The reaction mixture was stirred at
room temperature for 3 h. The reaction mixture was concentrated by
high vacuum pump to afford 69 mg (98.9%) of off-white solid product
1-(piperidin-4-ylamino)-3-(pyridin-4-yloxy)-propan-2-ol 3HCl salt.
ES.sup.+ 252.41 m/z (MH.sup.+)
[0197] To a sealed tube was added trifluoro-methanesulfonic acid
6-carbamoylmethylsulfanyl-5-cyano-4-propyl-pyridin-2-yl ester (66.7
mg, 0.174 mmol) in 4 mL of dry DMF, followed by the addition of
1-(piperidin-4-ylamino)-3-(pyridin-4-yloxy)-propan-2-ol
trihydrochloride salt (69 mg, 0.191 mmol) and
N--N-diisopropylethylamine (180 mg, 1.39 mmol). The reaction
mixture was stirred at 70.degree. C. for 2 h. DMF was removed in
vacuo. The residue was dissolved in 5 mL of MeOH, followed by the
addition of sodium methoxide, 0.5 M solution in MeOH (1.74 mL, 0.86
mmol). The reaction mixture was stirred at 70.degree. C. for 2 h.
The reaction mixture was concentrated in vacuo. The residue was
loaded onto a flash chromatography column. The column was eluted
with 0-5% 2M NH.sub.3 in MeOH/CH.sub.2Cl.sub.2. The product
fractions were collected, concentrated and dried under high vacuum
pump to afford 24 mg (28.5%) of the title compound as a light brown
solid product. (TLC: Rf=0.4, 5% 2M NH.sub.3 in
MeOH/CH.sub.2Cl.sub.2, UV). ES.sup.+ 485.29 m/z (MH.sup.+)
[0198]
3-Amino-6-{4-[2-hydroxy-3-(quinolin-4-yloxy)-propylamino]-piperidin-
-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide was
prepared via the methods described in example 17 and Scheme II.
ES.sup.+ 535.44 m/z (MH.sup.+)
[0199]
3-Amino-6-{4-[2-hydroxy-3-(isoquinolin-5-yloxy)-propylamino]-piperi-
din-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
was prepared via the methods described in example 17 and Scheme II.
ES.sup.+ 535.45 m/z (MH.sup.+)
[0200]
3-Amino-6-{4-[2-hydroxy-3-(quinolin-5-yloxy)-propylamino]-piperidin-
-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide was
prepared via the methods described in example 17 and Scheme II.
ES.sup.+ 535.30 m/z (MH.sup.+)
[0201]
3-Amino-6-{4-[2-hydroxy-3-(quinolin-6-yloxy)-propylamino]-piperidin-
-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide was
prepared via the methods described in example 17 and Scheme II.
ES.sup.+ 535.33 m/z (MH.sup.+)
[0202]
3-Amino-6-{4-[(S)-2-hydroxy-3-(quinolin-6-yloxy)-propylamino]-piper-
idin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide was prepared via the methods described in example 17 and
Scheme II. ES.sup.+ 561.31 m/z (MH.sup.+)
[0203]
3-Amino-6-{4-[(R)-2-hydroxy-3-(quinolin-6-yloxy)-propylamino]-piper-
idin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide was prepared via the methods described in example 17 and
Scheme II. ES.sup.+ 561.31 m/z (MH.sup.+)
[0204]
3-Amino-6-[4-(2-hydroxy-2-pyrimidin-5-yl-ethylamino)-piperidin-1-yl-
]-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
ES.sup.+ 482.30 m/z (MH.sup.+) was prepared via the methods
described in example 8 and scheme II.
[0205]
3-Amino-6-{4-[2-(6-bromo-pyridin-2-yl)-2-hydroxy-ethylamino]-piperi-
din-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acid
amide m/z (MH.sup.+) was prepared via the methods described in
example 8 and scheme II. ES.sup.+ 559.08/562.07
[0206]
3-Amino-6-{4-[2-hydroxy-2-(6-hydroxy-pyridin-2-yl)-ethylamino]-pipe-
ridin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide was prepared from 6-tert-Butoxy-pyridine-2-carbaldehyde
via the methods described in example 8 and scheme II. ES.sup.+
497.58 m/z (MH.sup.+)
[0207]
3-Amino-6-{4-[2-hydroxy-2-(6-hydroxy-pyridin-2-yl)-ethylamino]-pipe-
ridin-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
was prepared from 6-tert-Butoxy-pyridine-2-carbaldehyde via the
methods described in example 8 and scheme II. ES.sup.+ 471.35 m/z
(MH.sup.+)
[0208]
3-Amino-6-{4-[2-(6-chloro-pyridin-3-yl)-2-hydroxy-ethylamino]-piper-
idin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide was prepared via the methods described in example 8 and
scheme II. ES.sup.+ 515.49/517.49 m/z (MH.sup.+)
[0209]
3-Amino-6-{4-[2-hydroxy-2-(6-methoxy-pyridin-3-yl)-ethylamino]-pipe-
ridin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide was prepared via the methods described in example 8 and
scheme II. ES.sup.+ 511.45 m/z (MH.sup.+)
[0210]
3-Amino-6-{4-[2-hydroxy-2-(1-methyl-1H-imidazol-2-yl)-ethylamino]-p-
iperidin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide was prepared via the methods described in example 1 and
scheme II. ES.sup.+ 484.23 m/z (MH.sup.+)
[0211]
3-Amino-6-{4-[2-hydroxy-2-(2-methyl-3H-imidazol-4-yl)-ethylamino]-p-
iperidin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide was prepared via the methods described in example 12 and
scheme II. ES.sup.+ 484.13 m/z (MH.sup.+)
[0212]
3-Amino-6-{4-[2-hydroxy-2-(2-hydroxy-pyridin-4-yl)-ethylamino]-pipe-
ridin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide was prepared from 2-Hydroxy-pyridine-4-carbaldehyde via
the methods described in example 12 and scheme II. ES.sup.+ 497.37
m/z (MH.sup.+)
[0213] 2-Hydroxy-pyridine-4-carbaldehyde was available from
4-Methyl-pyridin-2-ol as described in J. Am. Chem Soc. 1997 115,
3619.
Example 18
3-Amino-6-[4-(2-[3,3']bipyridinyl-6-yl-2-hydroxy-ethylamino)-piperidin-1-y-
l]-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acid
amide
##STR00141##
[0215] An N.sub.2-purged suspension of
[2-(5-Bromo-pyridin-2-yl)-2-hydroxy-ethyl]-carbamic acid tert-butyl
ester (460 mg, 1.45 mmol),
tetrakis(triphenylphosphine)-palladium(0) (168 mg, 0.145 mmol),
potassium carbonate (401 mg, 2.90 mmol), and pyridine-3-boronic
acid (207 mg, 1.60 mmol) in dry DMF (15 ml) and water (3 ml) was
sealed and heated to 85.degree. C. for 18 h. The reaction was
quenched with 100 ml water and extracted with 3.times.150 ml ethyl
acetate. The combined organic phases were dried with
Na.sub.2SO.sub.4, filtered and concentrated in vacuo. The residue
was dissolved in a small amount of DMF, applied to a celite plug,
and purified by SiO.sub.2 chromatography (0-100%
EtOAc/CH.sub.2Cl.sub.2, then 0-25% MeOH/EtOAc) to give 442 mg,
87.0%, of (2-[3,3']Bipyridinyl-6-yl-2-hydroxy-ethyl)-carbamic acid
tert-butyl ester ES.sup.+ 316.5 m/z (MH.sup.+).
[0216]
3-Amino-6-[4-(2-[3,3']bipyridinyl-6-yl-2-hydroxy-ethylamino)-piperi-
din-1-yl]-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acid
amide was prepared via the methods described in scheme II.
[0217]
3-Amino-6-{4-[2-hydroxy-2-(5-quinolin-3-yl-pyridin-2-yl)-ethylamino-
]-piperidin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide was prepared via the methods described in example 18 and
Scheme II. ES.sup.+ 608.6 m/z (MH.sup.+)
[0218]
3-Amino-6-{4-[2-hydroxy-2-(5-phenyl-pyridin-2-yl)-ethylamino]-piper-
idin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide was prepared via the methods described in example 18 and
Scheme II. ES.sup.+ 557.7 m/z (MH.sup.+)
[0219]
3-Amino-6-{4-[2-(6'-dimethylamino-[3,3']bipyridinyl-6-yl)-2-hydroxy-
-ethylamino]-piperidin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-car-
boxylic acid amide was prepared via the methods described in
example 18 and Scheme II. ES.sup.+ 601.9 m/z (MH.sup.+)
[0220]
3-Amino-6-{4-[2-hydroxy-2-(5-pyrimidin-5-yl-pyridin-2-yl)-ethylamin-
o]-piperidin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide was prepared via the methods described in example 18 and
Scheme II. ES.sup.+ 559.9 m/z (MH.sup.+)
[0221]
3-Amino-6-[4-(2-[3,4']bipyridinyl-6-yl-2-hydroxy-ethylamino)-piperi-
din-1-yl]-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acid
amide was prepared via the methods described in example 18 and
Scheme II. ES.sup.+ 558.9 m/z (MH.sup.+)
[0222]
3-Amino-6-{4-[2-hydroxy-2-(5-quinolin-8-yl-pyridin-2-yl)-ethylamino-
]-piperidin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide was prepared via the methods described in example 18 and
Scheme II. ES.sup.+ 608.9 m/z (MH.sup.+)
[0223]
3-Amino-6-{4-[2-hydroxy-2-(5-isoquinolin-4-yl-pyridin-2-yl)-ethylam-
ino]-piperidin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide was prepared via the methods described in example 18 and
Scheme II. ES.sup.+ 608.8 m/z (MH.sup.+)
[0224]
3-Amino-6-{4-[2-(5-bromo-pyridin-2-yl)-2-hydroxy-ethylamino]-piperi-
din-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acid
amide was prepared via the methods described in example 1 and
scheme II. ES.sup.+ 559.6/561.6 m/z (MH.sup.+)
Example 19
3-Amino-6-(4-{2-hydroxy-2-[5-(3-methanesulfonyl-phenyl)-pyridin-2-yl]-ethy-
lamino}-piperidin-1-yl)-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxyl-
ic acid amide
##STR00142##
[0226] A N.sub.2-purged suspension of
3-Amino-6-{4-[2-(5-bromo-pyridin-2-yl)-2-hydroxy-ethylamino]-piperidin-1--
yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
(60 mg, 0.107 mmol), (3-methylsulfonylphenyl)boronic acid (24 mg,
0.118 mmol), tetrakis(triphenylphosphine)palladium(0) (19 mg, 0.016
mmol), and potassium carbonate (30 mg, 0.214 mmol) in dry DMF (4
ml) and water (1 ml) was sealed and heated to 85.degree. C. for 18
h. The crude reaction mixture was applied to a celite plug and
purified by SiO.sub.2 chromatography (0-25% MeOH/CH.sub.2Cl.sub.2
with 1% NH.sub.4OH). Fractions containing product were pooled and
concentrated. The solid yellow residue was dissolved in 1 ml DMF,
applied to a 2 mm prep plate (Merck) and eluted twice with 10%
MeOH/CH.sub.2Cl.sub.2 with 1% NH.sub.4OH. The recovered yellow
residue was dissolved in 0.5 ml water, 2 ml MeOH, 10 ml
CH.sub.2Cl.sub.2, and 10 ml EtOAc and crystallized by the addition
of 50 ml hexanes to give 29.0 mg, 42.3% of
3-Amino-6-(4-{2-hydroxy-2-[5-(3-methanesulfonyl-phenyl)-pyridin-2-yl]-eth-
ylamino}-piperidin-1-yl)-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxy-
lic acid amide product. ES.sup.+ 635.1 m/z (MH.sup.+).
[0227]
3-Amino-6-(4-{2-hydroxy-2-[5-(3-hydroxy-phenyl)-pyridin-2-yl]-ethyl-
amino}-piperidin-1-yl)-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxyli-
c acid amide was prepared via the methods described in example 19
and Scheme II. ES.sup.+ 573.1 m/z (MH.sup.+)
[0228]
3-Amino-6-(4-{2-hydroxy-2-[5-(3-methanesulfonylamino-phenyl)-pyridi-
n-2-yl]-ethylamino}-piperidin-1-yl)-4-trifluoromethyl-thieno[2,3-b]pyridin-
e-2-carboxylic acid amide was prepared via the methods described in
example 19 and Scheme II. ES.sup.+ 650.2 m/z (MH.sup.+)
[0229]
3-Amino-6-(4-{2-hydroxy-2-[5-(3-hydroxymethyl-phenyl)-pyridin-2-yl]-
-ethylamino}-piperidin-1-yl)-4-trifluoromethyl-thieno[2,3-b]pyridine-2-car-
boxylic acid amide was prepared via the methods described in
example 19 and Scheme II. ES.sup.+ 587.3 m/z (MH.sup.+)
[0230]
3-Amino-6-(4-{2-[5-(3-amino-phenyl)-pyridin-2-yl]-2-hydroxy-ethylam-
ino}-piperidin-1-yl)-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide was prepared via the methods described in example 19 and
Scheme II. ES.sup.+ 572.4 m/z (MH.sup.+)
[0231]
3-Amino-6-(4-{2-[5-(3-dimethylamino-phenyl)-pyridin-2-yl]-2-hydroxy-
-ethylamino}-piperidin-1-yl)-4-trifluoromethyl-thieno[2,3-b]pyridine-2-car-
boxylic acid amide was prepared via the methods described in
example 19 and Scheme II. ES.sup.+ 600.2 m/z (MH.sup.+)
[0232]
3-Amino-6-(4-{2-hydroxy-2-[5-(3-methylcarbamoyl-phenyl)-pyridin-2-y-
l]-ethylamino}-piperidin-1-yl)-4-trifluoromethyl-thieno[2,3-b]pyridine-2-c-
arboxylic acid amide was prepared via the methods described in
example 19 and Scheme II. ES.sup.+ 614.3 m/z (MH.sup.+)
[0233]
3-Amino-6-(4-{2-[5-(3-dimethylcarbamoyl-phenyl)-pyridin-2-yl]-2-hyd-
roxy-ethylamino}-piperidin-1-yl)-4-trifluoromethyl-thieno[2,3-b]pyridine-2-
-carboxylic acid amide was prepared via the methods described in
example 19 and Scheme II. ES.sup.+ 628.3 m/z (MH.sup.+)
[0234]
6-(4-{2-[5-(3-Acetylamino-phenyl)-pyridin-2-yl]-2-hydroxy-ethylamin-
o}-piperidin-1-yl)-3-amino-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carbo-
xylic acid amide was prepared via the methods described in example
19 and Scheme II. ES.sup.+ 614.3 m/z (MH.sup.+)
[0235]
3-Amino-6-{4-[2-(6'-amino-[3,3']bipyridinyl-6-yl)-2-hydroxy-ethylam-
ino]-piperidin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide was prepared via the methods described in example 19 and
Scheme II. ES.sup.+ 573.3 m/z (MH.sup.+)
[0236]
3-Amino-6-(4-{2-[5-(3-carbamoyl-phenyl)-pyridin-2-yl]-2-hydroxy-eth-
ylamino}-piperidin-1-yl)-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxy-
lic acid amide was prepared via the methods described in example 19
and Scheme II. ES.sup.+ 600.3 m/z (MH.sup.+)
[0237]
3-Amino-6-[4-(2-hydroxy-2-{5-[3-(morpholine-4-carbonyl)-phenyl]-pyr-
idin-2-yl}-ethylamino)-piperidin-1-yl]-4-trifluoromethyl-thieno[2,3-b]pyri-
dine-2-carboxylic acid amide was prepared via the methods described
in example 19 and Scheme II. ES.sup.+ 670.4 m/z (MH.sup.+)
[0238]
3-Amino-6-(4-{2-hydroxy-2-[5-(2-methoxy-pyrimidin-5-yl)-pyridin-2-y-
l]-ethylamino}-piperidin-1-yl)-4-trifluoromethyl-thieno[2,3-b]pyridine-2-c-
arboxylic acid amide was prepared via the methods described in
example 19 and Scheme II. ES.sup.+ 589.3 m/z (MH.sup.+)
[0239]
3-Amino-6-{4-[2-hydroxy-2-(6'-methoxy-[3,3']bipyridinyl-6-yl)-ethyl-
amino]-piperidin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxyli-
c acid amide was prepared via the methods described in example 19
and Scheme II. ES.sup.+ 588.4 m/z (MH.sup.+)
Example 20
3-Amino-6-(4-{2-hydroxy-2-[5-(2-oxo-2,3-dihydro-1H-indol-6-yl)-pyridin-2-y-
l]-ethylamino}-piperidin-1-yl)-4-trifluoromethyl-thieno[2,3-b]pyridine-2-c-
arboxylic acid amide
##STR00143##
[0241] An N.sub.2-purged suspension of
3-Amino-6-{4-[2-(5-bromo-pyridin-2-yl)-2-hydroxy-ethylamino]-piperidin-1--
yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
(150 mg, 0.268 mmol), bis(pinacolato)diboron (153 mg, 0.590 mmol),
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)-CH.sub.2Cl.su-
b.2 complex (33 mg, 0.040 mmol), and potassium acetate (133 mg,
1.34 mmol) in dry DMF (4 ml) was heated at 80.degree. C. for 2.5 h.
The crude reaction mixture was then added directly via syringe to a
stirring, N.sub.2-purged suspension of 6-bromo-2-oxindole (65 mg,
0.295 mmol), tetrakis(triphenylphosphine)palladium(0) (47 mg, 0.040
mmol), and potassium carbonate (74 mg, 0.536 mmol) in dry DMF (6
ml) and water (2 ml) at rt. The sealed mixture was heated to
85.degree. C. for 4 h. The crude reaction was applied directly to a
SiO.sub.2 column and purified (0-25% MeOH/CH.sub.2Cl.sub.2 with
NH.sub.4OH). Fractions containing desired product were pooled and
concentrated. The yellow residue was dissolved in 2 ml DMF and
applied to a 2 mm prep plate (Merck) eluting with 10%
MeOH/CH.sub.2Cl.sub.2 with 1% NH.sub.4OH. The yellow product
crystallized at the origin and the impurities were removed by being
carried up the plate. The recovered yellow residue was dissolved in
1 ml DMF, 2 ml MeOH, 5 ml EtOAc, and 5 ml CH.sub.2Cl.sub.2 and
crystallized by the addition of 30 ml hexanes to give 20.5 mg,
11.9% of
3-Amino-6-(4-{2-hydroxy-2-[5-(2-oxo-2,3-dihydro-1H-indol-6-yl)-pyridin-2--
yl]-ethylamino}-piperidin-1-yl)-4-trifluoromethyl-thieno[2,3-b]pyridine-2--
carboxylic acid amide product. ES.sup.+ 612.4 m/z (MH.sup.+).
[0242]
3-Amino-6-(4-{2-hydroxy-2-[5-(2-oxo-2,3-dihydro-1H-indol-5-yl)-pyri-
din-2-yl]-ethylamino}-piperidin-1-yl)-4-trifluoromethyl-thieno[2,3-b]pyrid-
ine-2-carboxylic acid amide was prepared via the methods described
in example 20 and Scheme II. ES.sup.+ 612.5 m/z (MH.sup.+)
[0243]
3-Amino-6-{4-[2-hydroxy-2-(5-thiazol-2-yl-pyridin-2-yl)-ethylamino]-
-piperidin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide was prepared via the methods described in example 20 and
Scheme II. ES.sup.+ 564.4 m/z (MH.sup.+)
[0244]
3-Amino-6-[4-(2-hydroxy-2-quinolin-8-yl-ethylamino)-piperidin-1-yl]-
-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide was
prepared via the methods described in example 8 and Scheme II.
ES.sup.+: 505.60 m/z (MH.sup.+)
[0245]
3-Amino-6-[4-(2-hydroxy-2-quinolin-8-yl-ethylamino)-piperidin-1-yl]-
-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
was prepared via the methods described in example 8 and Scheme II.
ES.sup.+ 531.64 m/z (MH.sup.+)
Example 21
3-Amino-6-{4-[2-hydroxy-2-(2-phenyl-1H-benzoimidazol-5-yl)-ethylamino]-pip-
eridin-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid
amide
##STR00144##
[0247] 3,4-Diamino-benzoic acid methyl ester (2 g, 12.035 mmol) was
dispersed in 40 mL DCM. Added hunig's base (2.516 mL, 14.442 mmol)
and stirred at RT until everything was in solution. Added benzoyl
chloride (1.397 mL, 12.035 mmol) dropwise into the mixture and
stirred at RT for 1 hour. Added sat. NaHCO3 aq. solution into the
reaction mixture. Extracted with DCM three times. Combined all
organic extracts and washed with brine. Dried over Na2SO4. Filtered
and removed solvent in vacuo. Purified by flash chromatography
using 10% MeOH/DCM as eluent mixtures.
4-Amino-3-benzoylamino-benzoic acid methyl ester was trituated in
hot ethyl acetate and 1.667 g (51.2%) white solid was obtained.
[0248] Cyclization to benzimidazole was using the procedure found
in Tetrahedron 2001, 57 (9), 1793-1799
[0249] 2-Phenyl-1H-benzoimidazole-5-carboxylic acid methyl ester
(1.178 g, 4.67 mmol) was dissolved in 20 mL THF. Cooled to
0.degree. C. and then added LAH (886 mg, 23.35 mmol). The mixture
was heated to 50.degree. C. overnight. Added 0.9 mL water, 0.9 mL
15% NaOH aqu. solution then 3 mL water. Stirred at RT for 30 mins.
Filtered through celite and washed the celite with ethyl acetate.
Washed the filtrate with brine. Dried over Na2SO4. Filtered and
removed solvent in vacuo. Obtained 783 mg (74.8%) of
(2-Phenyl-1H-benzoimidazol-5-yl)-methanol as an off white foam.
[0250] (2-Phenyl-1H-benzoimidazol-5-yl)-methanol (783 mg, 3.49
mmol) was dissolved in 20 mL THF. Added MnO2 (3.035 g, 34.91 mmol)
and stirred at RT for 1 hour. Filtered through celite and removed
solvent in vacuo. Obtained 769 mg (99.1%) of
2-Phenyl-1H-benzoimidazole-5-carbaldehyde as a light yellow
foam.
[0251]
3-Amino-6-{4-[2-hydroxy-2-(2-phenyl-1H-benzoimidazol-5-yl)-ethylami-
no]-piperidin-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide was prepared via the methods described in example 2 and
Scheme II. ES.sup.+ 570.57 m/z (MH.sup.+)
[0252]
3-Amino-6-{4-[2-hydroxy-2-(2-phenyl-1H-benzoimidazol-5-yl)-ethylami-
no]-piperidin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide was prepared via the methods described in example 21,
example 2 and Scheme II. ES.sup.+ 596.54 m/z (MH.sup.+)
[0253]
3-Amino-6-{4-[2-hydroxy-2-(2-isopropyl-1H-benzoimidazol-5-yl)-ethyl-
amino]-piperidin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxyli-
c acid amide was prepared via the methods described in example 21,
example 2 and Scheme II. ES.sup.+ 562.54 m/z (MH.sup.+)
Example 22
3-Amino-6-[4-((R)-2-hydroxy-2-pyridin-2-yl-ethylamino)-piperidin-1-yl]-4-t-
rifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
[0254] The enantioselective synthesis of
2-chloro-6-(R)-oxiranyl-pyridine was accomplished in 89% ee using
(+)-DIP Chloride according to the method described by Merck and
Co., U.S. Pat. No. 5,561,142, Oct. 1, 1996, starting from
6-hydroxypicolinic acid.
##STR00145##
[0255] The 2-Chloro-6-(S)-oxiranyl-pyridine was opened with
tert-butyl-4-amino-1-piperidine-carboxylate in the presence of
lithium perchlorate (see Scheme above). The resulting
4-[(R)-2-(6-chloro-pyridin-2-yl)-2-hydroxy-ethylamino]-piperidine-1-carbo-
xylic acid tert-butyl ester was dechlorinated by transfer
hydrogenation from ammonium formate and 10% palladium-on-carbon in
70% yield.
[0256] The piperidine was then de-protected by treatment with HCl
in 1,4-dioxane/methanol as described before, in quantitative yield.
3-Amino-6-[4-((R)-2-hydroxy-2-pyridin-2-yl-ethylamino)-piperidin-1-yl]-4--
trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acid amide 95.0%
ee, Mp: 165-167.degree. C. was prepared via the methods described
in scheme II. ES.sup.+ 481 m/z (MH.sup.+)
[0257]
3-Amino-6-[4-((S)-2-hydroxy-2-pyridin-2-yl-ethylamino)-piperidin-1--
yl]-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acid amide
95.4% ee, Mp: 165-167.degree. C. was prepared via the methods
described in example 22 and scheme II. ES.sup.+ 481 m/z
(MH.sup.+)
[0258]
3-Amino-6-{4-[(S)-2-(6-chloro-pyridin-2-yl)-2-hydroxy-ethylamino]-p-
iperidin-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid
amide was prepared via the methods described in example 22 and
scheme II. ES.sup.+ 489.56 m/z (MH.sup.+)
[0259]
3-Amino-6-{4-[(R)-2-(6-chloro-pyridin-2-yl)-2-hydroxy-ethylamino]-p-
iperidin-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid
amide was prepared via the methods described in example 22 and
scheme II. ES.sup.+ 489.54 m/z (MH.sup.+)
[0260]
3-Amino-6-{4-[(S)-2-(6-chloro-pyridin-2-yl)-2-hydroxy-ethylamino]-p-
iperidin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide was prepared via the methods described in example 22 and
scheme II. ES.sup.+ 515.37/517.37 m/z (MH.sup.+)
[0261]
3-Amino-6-{4-[(R)-2-(6-chloro-pyridin-2-yl)-2-hydroxy-ethylamino]-p-
iperidin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide was prepared via the methods described in example 22 and
scheme II. ES.sup.+ 515.33/517.33 m/z (MH.sup.+)
Example 23
3-Amino-6-{4-[(R)-2-hydroxy-2-(6-methyl-pyridin-2-yl)-ethylamino]-piperidi-
n-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acid
amide
##STR00146##
[0263] 2-Methyl-6-oxiranyl-pyridine (9.49 g, 70.29 mmol) was
dissolved into 50 mL of CH.sub.3CN. To this was added sodium azide
(5.53 g, 85.00 mmol) and lithium perchlorate (9.043 g, 85.00 mmol).
The mixture stirred overnight. LC-MS analysis indicated a complete
reaction. Concentrated the mixture to a thick oil. Dissolved in
CH.sub.2Cl.sub.2, applied to a SiO.sub.2 column and purified (20%
EtOAc/hexanes) to give 5.00 g of
2-azido-1-(6-methyl-pyridin-2-yl)-ethanol.
[0264] Dissolved 2-Azido-1-(6-methyl-pyridin-2-yl)-ethanol (4.300
g, 24.130 mmol) into 200 mL of toluene. To this was added vinyl
acetate (9.22 mL, 100.00 mmol) and Lipase PS-C II (4.00 g). The
mixture stirred for 4.5 h at RT and was monitored by .sup.1H NMR.
The reaction mixture was filtered through a bed of celite and
rinsed with 100 mL of toluene. The filtrate was concentrated in
vacuo. Dissolved residue into CH.sub.2Cl.sub.2, applied to a
SiO.sub.2 Column and purified (5-30% EtOAc/hexanes) to give 2.20 g
of acetic acid (R)-2-azido-1-(6-methyl-pyridin-2-yl)-ethyl ester
and 2.11 of (S)-2-azido-1-(6-methyl-pyridin-2-yl)-ethanol, ee
%>99.
[0265] Dissolved acetic acid
(R)-2-azido-1-(6-methyl-pyridin-2-yl)-ethyl ester (2.20 g, 9.90
mmol) into 50 mL of MeOH. To this was added K.sub.2CO.sub.3 (1.50
g) and the heterogenous mixture stirred for 2 h. LC-MS analysis
indicated completion of the reaction. The mixture was concentrated
and 100 mL of H.sub.2O was added. The mixture was extracted with
2.times.100 mL of CH.sub.2Cl.sub.2, dried with MgSO.sub.4, filtered
and concentrated to give 1.78 g of
(R)-2-azido-1-(6-methyl-pyridin-2-yl)-ethanol. ee %>99.
[0266] Suspended 10% Pd/C (0.50 g) into 100 mL EtOH under Ar. To
this was added (R)-2-azido-1-(6-methyl-pyridin-2-yl)-ethanol (3.57
g, 20.74 mmol). The reaction was placed under atm. H.sub.2 for 12
h. LC-MS analysis indicted some remaining azide. Recharge with
H.sub.2 atmosphere and stir an additional 12 h. LC-MS analysis
indicated complete reaction. The mixture was filtered through a bed
of celite. The celite was rinsed with 100 mL of EtOH. The filtrate
was concentrated to give 2.99 g of
(R)-2-amino-1-(6-methyl-pyridin-2-yl)-ethanol.
[0267]
3-Amino-6-{4-[(S)-2-hydroxy-2-(6-methyl-pyridin-2-yl)-ethylamino]-p-
iperidin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide was prepared via the methods described in example 6 and
scheme II. ES.sup.+ 495.54 m/z (MH.sup.+)
[0268]
3-Amino-6-{4-[(S)-2-hydroxy-2-(6-methyl-pyridin-2-yl)-ethylamino]-p-
iperidin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide was prepared from
(S)-2-azido-1-(6-methyl-pyridin-2-yl)-ethanol via the methods
described in example 6 and scheme II. ES.sup.+ 495.24 m/z
(MH.sup.+)
##STR00147##
[0269]
3-Amino-6-{4-[2-(2-benzyl-1H-benzoimidazol-5-yl)-2-hydroxy-ethylami-
no]-piperidin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide was prepared via the methods described in example 21,
example 2 and Scheme II. ES.sup.+ 610.5 m/z (MH.sup.+).
[0270]
3-Amino-6-(4-{2-hydroxy-2-[5-(3-methyl-3H-imidazol-4-yl)-pyridin-2--
yl]-ethylamino}-piperidin-1-yl)-4-trifluoromethyl-thieno[2,3-b]pyridine-2--
carboxylic acid amide. was prepared via the methods described in
example 20 and Scheme II. ES.sup.+ 608.4 m/z (MH.sup.+). ES.sup.+
561.4 m/z (MH.sup.+).
[0271]
3-Amino-6-{4-[2-hydroxy-2-(6-phenyl-pyridin-3-yl)-ethylamino]-piper-
idin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide was prepared via the methods described in example 19 and
Scheme II. ES.sup.+ 557.5 m/z (MH.sup.+).
[0272]
3-Amino-6-[4-(2-[2,3']bipyridinyl-5-yl-2-hydroxy-ethylamino)-piperi-
din-1-yl]-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acid
amide was prepared via the methods described in example 19 and
Scheme II. ES.sup.+ 558.5 m/z (MH.sup.+).
[0273]
3-Amino-6-{4-[2-hydroxy-2-(6-pyrimidin-5-yl-pyridin-3-yl)-ethylamin-
o]-piperidin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide was prepared via the methods described in example 19 and
Scheme II. ES.sup.+ 559.5 m/z (MH.sup.+).
[0274]
3-Amino-6-(4-{2-hydroxy-2-[6-(2-methoxy-pyrimidin-5-yl)-pyridin-3-y-
l]-ethylamino}-piperidin-1-yl)-4-trifluoromethyl-thieno[2,3-b]pyridine-2-c-
arboxylic acid amide was prepared via the methods described in
example 19 and Scheme II. ES.sup.+ 589.5 m/z (MH.sup.+).
[0275]
3-Amino-6-{4-[2-hydroxy-2-(6'-methoxy-[2,3']bipyridinyl-5-yl)-ethyl-
amino]-piperidin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxyli-
c acid amide was prepared via the methods described in example 19
and Scheme II. ES.sup.+ 588.5 m/z (MH.sup.+).
[0276]
3-Amino-6-{4-[2-hydroxy-2-(6-quinolin-8-yl-pyridin-3-yl)-ethylamino-
]-piperidin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide was prepared via the methods described in example 19 and
Scheme II. ES.sup.+ 608.4 m/z (MH.sup.+).
[0277]
3-Amino-6-{4-[2-(6-bromo-pyridin-3-yl)-2-hydroxy-ethylamino]-piperi-
din-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acid
amide. was prepared via the methods described in example 8 and
Scheme II. ES.sup.+ 608.4 m/z (MH.sup.+). ES.sup.+ 559.3/561.3 m/z
(MH.sup.+).
[0278]
3-Amino-6-{4-[2-(6-carbamoylmethylsulfanyl-pyridin-3-yl)-2-hydroxy--
ethylamino]-piperidin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carb-
oxylic acid amide was a side product of the preceeding example
ES.sup.+ 570.5 m/z (MH.sup.+).
[0279]
3-Amino-6-{4-[2-hydroxy-2-(6-methoxy-pyridin-2-yl)-ethylamino]-pipe-
ridin-1-yl}-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic
acid amide was prepared via the methods described in example 1 and
Scheme II. ES.sup.+ 511.3 m/z (MH.sup.+).
Assessment of Biological Properties
[0280] The inhibition of IKK.alpha. and IKK.beta. by the compounds
of the present invention was determined with the following assay
that measures the phosphorylation of the I.kappa.B.alpha. substrate
by the respective kinases. The enzymes used in the assay were
N-terminally flag-tagged versions of the human IKK.beta. or
IKK.alpha. and the substrate was a GST fusion protein with
I.kappa.B.alpha. (amino acids 1-54).
[0281] The reaction mixtures (60 .mu.l) contained 20 mM HEPES pH
7.5, 10 mM MgCl.sub.2, 2 mM MnCl.sub.2, 100 mM NaCl, 100 .mu.M
Na.sub.3VO.sub.4, 20 mM .beta.-glycerophosphate, 1 mM DTT, 2% DMSO,
250 nM ATP, 0.4 nM [.sup.33P]ATP (specific activity, 3000 Ci/mmol),
I.kappa.B.alpha. substrate, IKK enzyme and test compound. The
reaction mixtures contained either 3.6 .mu.g/ml IKK.alpha. and 245
.mu.g/ml I.kappa.B.alpha. or 0.9 .mu.g/ml IKK.beta. and 53 .mu.g/ml
I.kappa.B.alpha..
[0282] Reactions were initiated by adding a solution of
I.kappa.B.alpha. substrate and ATP to polypropylene plates
containing IKK enzyme that was pre-incubated for 5 minutes with
test compound. Then the reaction mixtures were incubated for 1 hour
at 25.degree. C., placed on ice and quenched by the addition of 150
.mu.l 10% trichloroacetic acid and 5% disodium pyrophosphate. After
mixing, the entire contents of the quenched reaction mixtures were
transferred to a pre-wetted Packard UniFilter filtration plate,
aspirated and washed 6 times with 250 .mu.l of ddH.sub.2O using the
Packard Filtermate Harvester. Filtration plates were then air
dried, supplemented with 40 .mu.l of Microscint 20 scintillation
fluid and the .sup.33P-labeled reaction products were quantified
using the Packard TopCount scintillation counter.
[0283] Compounds were tested in three-fold serial dilutions and
inhibitor concentrations to achieve 50% inhibition of enzyme
activity (i.e., IC.sub.50) were derived from dose-response curves
using SAS software (SAS Institute, Cary N.C.). A non-linear
regression analysis based on the Hill equation was applied to the
percent inhibition versus concentration data. In all cases,
compound concentrations were verified by HPLC.
[0284] Compounds in the Table in the Detailed Description of the
Invention section were all evaluated in the assay for IKK.beta.
inhibition and had IC.sub.50's of about 1 .mu.M or below.
[0285] The compounds were all also evaluated in the assay for
IKK.alpha. inhibition and had IC.sub.50's of about 20 .mu.M or
below.
* * * * *